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Abstract
MULTI-PLATFORM ARABINOXYLAN SCAFFOLDS AS POTENTIAL WOUND
DRESSING MATERIALS
By Donald Chukwuemeka Aduba, Jr., Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Biomedical Engineering at Virginia Commonwealth University.
Virginia Commonwealth University, 2015
Research Director: Dr. Hu Yang
Associate Professor, Biomedical Engineering
Biopolymers are becoming more attractive as advanced wound dressings because of their
naturally derived origin, abundance, low cost and high compatibility with the wound
environment. Arabinoxylan (AX) is a class of polysaccharide polymers derived from cereal
grains that are primarily used in food products and cosmetic additives. Its application as a wound
dressing material has yet to be realized. In this two-pronged project, arabinoxylan ferulate (AXF)
was fabricated into electrospun fibers and gel foams to be evaluated as platforms for wound
dressing materials. In the first study, AXF was electrospun with varying amounts of gelatin. In
the second study, AXF was dissolved in water, enzymatically crosslinked and lyophilized to
form gel foams. The morphology, mechanical properties, porosity, drug release kinetics,
fibroblast cell response and anti-microbial properties were examined for both platforms.
Carbohydrate assay was conducted to validate the presence of arabinoxylan ferulate in the
electrospun GEL-AXF fibers. Swelling and endotoxin quantification studies were done to
evaluate the absorptive capacity and sterilization agent efficacy respectively in AXF foams. The
results indicated successful fabrication of both platforms which validated the porous, absorptive,
biocompatibility and drug release properties. The results also exhibited that silver impregnated
xiii

AXF scaffolds inhibited growth of Pseudomonas aeruginosa, Staphylococcus aureus and
Enterococcus faecalis bacteria species, anti-microbial properties necessary to function as
advanced wound dressing materials. Future work will be done to improve the stability of both
platforms as well as evaluate its applications in vivo.

Keywords: Absorptive, arabinoxylan, biocompatibility, non-toxic, advanced wound dressing,
foam, nanofiber, biopolymer
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CHAPTER 1: INTRODUCTION
Fabrication of a functional wound dressing material is critical in managing wound healing.
Wound dressing materials have been developed to help treat acute wounds by creating a moist
microenvironment conducive to regeneration of new tissue while preventing infection at the
injury site. An ideal wound healing material scaffold must possess the following properties to
help aid wound management and healing. It is expected to have good biocompatibility. It is
expected to have appropriate mechanical strength for insulation, wound protection and exudate
removal from the injury site. A wound dressing material should be absorptive, impermeable to
bacteria and inexpensive.
Many current wound dressing materials on the market possess the aforementioned properties
but none have used arabinoxylan (AX) as a base material. AX has the ability to absorb exudate at
the injury site. Thus, more research needs to be done to examine whether AX can serve as a
wound dressing material that facilitates efficient healing of acute, moderately exudating wounds.
AX possesses appropriate properties of an acute wound dressing material with potential to
improve exudate distribution and wound biological environment. AX is very hydrophilic and
possesses the ability to absorb large amounts of water – up to 100 grams of water per gram of
polymer. Also, it is bio-inert and not vulnerable to physical changes by surrounding ionic
environments.1 There is little research studying the biocompatibility of pure AX scaffolds in
vitro or in vivo. In this study, the physical and biocompatible properties of two arabinoxylan
ferulate (AXF) based formulations are evaluated:
1) Electrospun Arabinoxylan ferulate-Gelatin (GEL-AXF) nanofiber composites
2) Lyophilized Arabinoxylan ferulate (AXF) foams
1

These formulations studied highlight the versatility yet simple fabrication design for a
polymer that has an untapped niche in the wound dressing market. The goal of this study is to
investigate in vitro whether arabinoxylan ferulate based formulations are compatible wound
dressing materials aimed to treat acute, moderately exudating wounds.
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CHAPTER 2: Review of polysaccharides as wound dressing
materials
Donald C. Aduba, Jr.1, & Hu Yang1,2

1

Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, VA
23284
2

Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298.
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Abstract:
Longer life expectancies, an increased elderly population and a higher prevalence of
dietary disorders such as diabetes have led to an increased global demand for wound care.
Wound dressing materials are critical for wound care because they provide a physical barrier
between the injury site and outside environment, preventing the wound from further damage or
infection. Wound dressings also manage and even encourage the wound healing process. There
are many different types of wound dressings that exist in the market, applied specifically against
particular types of wound classified by their condition, shape and other pathologies to encourage
more efficient healing. Polysaccharide biopolymers are slowly becoming popular as modern
wound dressings because they are naturally derived, highly abundant, inexpensive, non-toxic and
non-immunogenic. However, there is no thorough review of this class of polymers and their
applications as wound dressing materials. This review primarily focuses on polysaccharide
platforms such as nanofibers and hydrogels designed and tested by research groups in vitro and
in vivo to evaluate their potential as wound dressing materials. In addition, a brief background of
the anatomy and physiology of skin, their function and relevance in wound healing is discussed.
Other important discussion points such as acute and chronic wound healing wound management
and wound dressing types are included. This comprehensive review will aim to focus on the
properties of polysaccharide materials which will hopefully be the impetus towards further
investigation of this class of polymers in wound dressing development.

Keywords: wound healing, wound dressing, foam, nanofiber, hydrogel, wound management, skin
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2.1 Introduction
Wound care due to traumatic injury, surgery, burns and disease is an overlooked but growing
problem in the United States. According to the National Center for Health Statistics, 40 million
inpatient surgical procedures were done in the United States in 2000.2 These procedures are
implicated in emergency care, natural disasters and in war battlefields. Unfortunately, over 6.5
million Americans suffer from chronic wounds post-surgery which leads to an estimated $6 to
$15 billion spent annually in health care costs.3 In 2010, the market for wound care products was
estimated at $15.3 billion.2 Acute wounds often arise from incisions of skin created from trauma,
surgery and superficial burns. Acute wounds typically heal quickly and tissue affected by the
incision is fully restored. However, chronic wounds which are more difficult to heal stem from
systemic diseases such as diabetes and obesity.2 Aging also plays a role in limiting wound
healing due to the skin losing elasticity with time. These wound pathologies will put a further
strain on hospitals globally with projected populations of individuals with diabetes, obesity and
being over 65 more than doubling by 2050.4, 5
Fabrication of a functional wound dressing material is critical in managing wound healing.
Wound dressing materials have been developed to help treat acute wounds by creating a moist
microenvironment conducive to regeneration of new tissue while preventing infection at the
injury site. A wound dressing material is expected to possess the following properties: It must
have good biocompatibility. It should have appropriate mechanical strength for insulation,
wound protection and exudate removal from the injury site. A wound dressing material is also
expected to be absorptive, impermeable to bacteria and inexpensive.
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2.2 Anatomy & physiology of skin
The skin is the largest organ of the body but also requires a lot of maintenance. This is
required for the skin to function in all the conditions faced by the body. The skin protects the rest
of the body from trauma, regulates the body temperature and is the first barrier of the immune
response. The skin also serves as a unit of metabolism and communication.6 The skin is the
largest organ in the body due to its large surface area. The skin of an adult covers 3000 square
inches and weighs approximately seven pounds because of the large volume. The skin also
demands over one-third of the body’s blood circulatory system. The skin’s large barrier allows
the internal organs to enjoy a homeostatic environment. Skin has an inherent ability to selfregenerate and can recover from mild injuries due to physical trauma or chemical damage.6 The
ability of the skin to recover may be dependent on where on the body the injury took place. The
skin thickness varies in different parts of the body for organ specific protection.6
The skin is broken down into two layers which provide different structural properties and
functions; the outer and inner layers are the epidermis and dermis respectively. Each layer has
sub-anatomic regions which have different functions. The epidermis is the outer most skin layer
which is avascular and has relatively uniform thickness throughout the body. The average
thickness of the epidermis is 75-150 µm although the palms and feet exhibit thicknesses between
400-600 µm.7
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Figure 2.1: Schema of anatomy of skin adapted from Hooper et al. [8]

2.2.1. Epidermis
The epidermal layer is comprised of keratinocyte epithelial cells which are further broken
down into the following five layers: stratum corneum, stratum lucidum, stratum granulosum,
stratum spinosum and stratum basale. (Figure 2.2) The stratum corneum is the top layer of the
epidermis and is made up of terminally differentiated keratinocytes. They are highly fibrous due
to keratin protein making up 80% of the cell. They are flat, pancake shaped, anucleated cells that
constantly slough off the skin during everyday activities such as handwashing, changing clothes,
bathing and exercising. Keratin’s highly fibrous nature allows the cells in this layer to withstand
7

environmental changes in pH and temperature. The stratum lucidum is a very thin layer beneath
the stratum corneum. It is only 1-5 cells thick and is typically absent from parts of the body
where the epidermis is not thick. In this layer, active lysosomes are present to degrade the
keratinocyte nucleus before they move up to the stratum corneum.9 The layer beneath the stratum
lucidum is the stratum granulosum. It is the granular layer in the epidermis whose cells are
diamond shaped in morphology. The cell’s nucleus is still active and has protein components
such as profilaggrin, intermediate keratin filaments and lorcrin that are organized by the
keratohyalin granules. This layer is only 1-5 cells thick. The stratum spinosum is beneath the
stratum granulosum and is a layer above the stratum basale. The stratum spinosum contains three
dimensional oblong shaped cells that has new batches of keratin filaments.10 It is the thickest of
the epidermal sublayers.

Figure 2.2: Schema of anatomy of subcutaneous tissue adapted from Hooper et al. [8]

Last, the basal layer of the epidermis, the stratum basale is home to keratinocytes that
actively respond to extracellular matrix, growth factors and other biological cues. Glucose
metabolism takes place in this layer as the metabolite permeates less to the upper layers in a
gradient fashion. The basal keratinocytes are very active by traveling through the epidermal
8

layers in approximately 28 days.10 During this migration process, the basal cells differentiate.
Also in the basal layer, exists the dermo-epidermal junction, which contains valleys called rete
ridges that help anchor the dermis in place and provide structural integrity. In addition, it is a
source of basal stem cells. These stem cells are slow growing but produce daughter transient
amplifying cells that make up 50% of the entire basal cell population. These cells have much
shorter mitotic cycles (36 hours) during wound healing compared normal keratinocyte cells (300
hours).11

2.2.2. Dermis
The dermis is the thickest layer of the skin and is highly vascularized and innervated. It is
modestly populated with fibroblasts. It has an average thickness of 2 mm and varies in different
parts of the body. The dermis’ vasculature allows the skin to receive nutrients and signals for
important functions in homeostasis, wound healing, immune response and inflammation. The
vasculature of the dermis also frequently involves angiogenesis due to the presence of important
growth factors such as vascular endothelial growth factor (VEGF), and fibroblast growth factor
(FGF). These growth factors are modulated by hypoxic conditions during the inflammatory stage
of wound healing or in tumor growth.6
The major proteins present in the dermis are: elastin and collagen. Within these protein
fibrils are ground substance which are matrix components comprised of proteoglycans (PGs) and
glycosaminoglycans (GAGs). PGs and GAGs provide flexibility to the dermal matrix because of
its high water absorption capability. Hyaluron is another matrix component which provides
binding sites for important growth factors and cells relevant to skin regeneration.12 Elastin is a
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secondary structural protein in the dermis that provides elastic properties to the skin. Elastin has
a coil configuration which winds and unwinds as it undergoes cyclic tension.13-15
All of the ECM components that build up the dermis are classified into two layers: the
papillary and reticular dermis. The papillary dermis is located at the dermo-epidermal junction
just below the epidermis. This area is made of interlocking papillary loops that provide blood
circulation and nutrients to the area. The collagen fibers are much smaller in this layer than the
reticular dermis but have more ground substance than the reticular layer. Meanwhile, the
reticular layer is the most basal layer in the dermis and contains larger collagen fibers with less
ground substance than the papillary layer.6
Collagen is the major structural protein and source of nourishment in the dermis.16 It is
produced by fibroblasts and its construction determines if the dermis is fully healed after
wounding. It makes up 25% of dry protein weight in mammals and is best known for its great
tensile strength. 17 Collagen is critical in wound healing because it serves as a reservoir for cell
attachment, proliferation and differentiation.18 It also is a guide for cell migration and helps
catalyze angiogenesis. Collagen is ubiquitous in the skin and native in organs throughout living
mammalian systems.18 There are two types of collagen primarily present in the body: type I and
III. Type I and III collagen composes of 77-85% and 15-23% of total collagen respectively.
There are other types of collagen such as type V and type VII that are present in trace amounts.19
Collagen in healthy dermis is a network of fibers intersecting perpendicularly into a woven mesh.
In compromised dermis tissue, collagen is poorly organized which leads to excessive scarring.16
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2.2.3. Skin function

The skin provides protection from mechanical trauma, injury from chemicals, pathogenic
infiltration and UV radiation. Skin is also key for water retention. A study in literature
highlighted individuals who had skin burns lose six times as much fluid as normal individuals.20
The skin is able to conserve the body’s general homeostasis because of its barrier like properties
that typically inhibits high molecular weight drug permeability. The tensile and elastic properties
of collagen and elastin give the skin strength to withstand forces.6
The stratum corneum is the primary line of defense against pathogenic organisms. This
layer eliminates microbes either through shedding or by function inhibition.21 During stratum
corneum shedding, microbes that would have otherwise been attached to the skin fall out. On the
other hand, the sebaceous glands in this layer produce a lipid substance called sebum which has a
slightly acidic pH range from 4 to 6.8.22 This acidic consistency with natural anti-bacterial
components in the substance prevent microbe growth. 22
Flora is present in the skin which also assists in reducing bacterial growth by inhibiting
its function.23 The key bacterial species inhibited by skin flora include: Staphylococcus aureus,
Streptococcus pyogenes and Pseudomonas aeruginosa.24 These bacterial species are pathogenic
and create chronic wounds because of producing high levels of toxins that lead overexpression of
inflammatory cytokines.25 Biofilm formation results from these bacteria after they become
embedded in a polysaccharide matrix. The biofilms can colonize and express resistance against
antibiotics and host immune response.26 Thus, it is important that skin flora can regulate levels of
pathogenic bacteria to prevent systemic inflammation and shock.
Several cell types within the skin are key players in the skin’s immune response. They are
Langerhans cells, mast cells, macrophages and dendrocytes. Langerhans cells are antigen
11

presenting cells that recognize and bind to T-cell receptors that destroy the invading microbe.
Tissue macrophages come from bone marrow derived monocytes and have a variety of functions.
First, they have a receptor which binds antigens on its surface that later is recognized by T-cells
in the immune response. They engulf and phagocytose microbes while producing important
growth factors and cytokines for wound healing and tissue remodeling.12 Mast cells are located
in the papillary dermis and at the junction between organ tissues and their surrounding
environments. They are called upon during inflammation to send chemical cues such as
histamine and vasodilators to induce phagocytosis of microbes, parasites and other injury debris
as wound healing transitions from the inflammation to proliferation stages.12 Dendrocytes are
located in the dermal layers and function primarily as phagocytic cells that are highly expressed
in diseased skin states.27
The skin thermally protects the body because it is a physical barrier between the internal
organs and outside environment. The skin also has more sophisticated physiological mechanisms
in place to control the body’s temperature. These mechanisms are through blood circulation and
sweating.6 Blood circulation in the skin can vasoconstrict to help the body retain heat in cold
environments. In hot environments, blood vessels vasodilate to release heat out of the skin to
help the body stay cool.9 In more pathological body states like a fever, the body needs to increase
its caloric and fluid uptake by 13% for every 1◦ C the body core temperature increases. During
rest, over 70% of heat production comes from the brain, trunk and visceral organs. In exercise,
the skin produces 90% of the heat output.28 Sweating is the other skin thermoregulation
mechanism dictated by the function of eccrine sweat glands. They are coils invaginated from the
epidermis to dermis layer. They are located mostly on the palms and soles of hands and shoes
respectively. There are 2 to 5 million of these glands with sizes of 0.05 to 0.1 millimeters.
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Eccrine glands are stimulated by temperature changes and nervous system effects. The sweat
glands produce fluids that are 99-99.5% water but also contain phosphate, urea, sulfate and
sodium chloride ions.22, 29 Sweating controls temperature either through the retention, release and
evaporation of sweat that maintains the body’s core temperature.

2.3 Wound healing process

The wound healing process is highly complex and requires extensive communication
among extracellular matrix components, cells and signaling factors that fluctuate during each of
the wound healing stages.16, 30 The acute wound healing process involves a progression of
connected stages where cellular and tissue matrix changes are made to help remodel damaged
tissue with new tissue. There are four stages in normal wound healing: hemostasis, inflammation,
proliferation and remodeling.31, 32 (Figure 2.3) Hemostasis begins immediately after the skin
undergoes an incision or trauma. Bleeding is initiated to wash out bacteria and other pathogenic
agents from the wound. Next, platelets are recruited to the injury site to minimize the bleeding,
protect the wound and recruit other cells involved in the wound healing response. Platelets create
a temporary extracellular matrix which become the destination of the recruited cells. 16 They also
activate the clotting cascade to produce tissue factor seven that leads to fibrin formation and a
scab at the injury site.31,33 The inflammation phase begins about one day after injury where
cytokines and chemokines produced by platelets activate vasodilation and angiogenesis of the
injured area. 16 Subsequently, leukocytes are recruited to destroy bacteria and later convert into
macrophages that engulf dead cells and debris, produce pro-inflammatory cytokines to recruit
fibroblasts and keratinocytes.16, 34 Recruited fibroblasts and keratinocytes secrete fibroblast
growth factor (FGF) and transforming growth factor (TGF-α) among other cell signals produced.
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Figure 2.3: The four phases of normal wound healing: 1) homeostasis, 2) inflammation, 3)
proliferation and 4) remodeling. Each step has many components. The pointed edge depicts an
ongoing process. Adapted from [35, 36]
In the proliferation stage one to three days post-injury, fibroblasts up-regulate receptor
expression to allow migration and anchoring of these cells to fibrin, fibronectin and vitronectin
present in the clot.37 Matrix metalloproteases (MMPs) are upregulated at the wound edge to
degrade ECM components at the clot. This enables keratinocytes to unbind from the clot and
migrate to the wound edge for wound epithelialization.38 Once the fibroblasts fully integrate in
the clot, they change into myofibroblasts and synthesize new extracellular matrix, made mostly
from collagen to rebuild the tissue. New blood vessels from granulation and increased expression
of vascular endothelial growth factor (VEGF) also take place to re-establish and strengthen the
injured wound closer to its original state before injury.16 A new layer of epithelial cells cover the
wound site on top of the granulating tissue to protect the wound. Last, in the remodeling phase,
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which can be up to a year after the original injury, fibroblast activity declines and collagen,
fibronectin and proteoglycans are remodeled and formed around the scar site.31 The remodeled
extracellular matrix is recovered but not perfectly back to its original form. In chronic wound
healing, macrophages are continuously recruited to the injured site, inducing production of
excess proteases and reactive oxygen species which constantly degrades the surrounding
extracellular matrix. The imbalance between matrix degradation and production prevents the
wound from progressing through the healing stages.39 As a result, tissue is repeatedly injured and
cannot heal over time. Figure 2.4 summarizes the differences between acute and chronic wound
healing.
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Figure 2.4: Normal versus chronic wound healing adapted from Nwomeh et al. [40]
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2.4 Wound management
Wound management is an important aspect of the wound healing process. Many different
types of wound dressings are available for particular wound conditions or etiologies. Wound
dressings are classified to help determine which type of wound dressing is most appropriate for a
specific application. Debridement is one characteristic that is very important for washing out
necrotic tissue and foreign material which would otherwise prolong the inflammatory phase.31
There are several debridement methods for treating necrotic wounds including: surgical removal,
wound irrigation and enzymes for material breakdown.31 Another approach described by
acronym TIME, Tissue assessment and management of tissue deficits, Inflammation and
Infection control, Moisture balance and Enhancing epithelial advancement around the wound
edges.41 The objective in choosing a wound dressing is to provide an environment at the wound
surface where it can completely heal at its maximum rate while maintaining a cosmetically
acceptable appearance.42 Usually a combination of dressings is needed to achieve this objective –
whether they are primary dressings that interface directly with the wound or secondary dressings
that cover and compress the primary dressing.
2.5 Modern wound dressings in the market classified by function
Many wound dressings are in the market to cover wounds specific to its size, shape,
moisture, adherence, material and antimicrobial properties.31 Wound dressings can also be
classified by the era of its development. Traditional wound dressings such as gauze and bandages
are the first type to be used for wound healing while more modern wound dressings create a
moist environment.31 Each type of dressing has strengths and weaknesses as well as a wound
environment where it is most effective. Traditional dressings are dry and are effective for
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insulation and protection from bacteria. However, they do not provide a moist environment and
have to be changed frequently to prevent the wound bed from drying out. They can also adhere
to the wound tissue which makes it painful to remove.31

Table 2.1 Classifications and examples of commercialized wound dressings by function
Adapted from References [43, 44]
Dressing
Classification

Dressing Type

Dressing Name

Manufacturer

Traditional

Gauze

First Aid Gauze Pads

Johnson & Johnson Healthcare

Sterile Gauze Pads

Medi-First

Sorbsan

Bertek Pharmaceuticals

Curasorb Calcium Alginate
Dressing

Tyco Healthcare/Kendall

Tegaderm

3M Healthcare

Purilon Gel

Coloplast Corp

Skintegrity Hydrogel

Medline Industries

Nu Gel Wound Dressing

Johnson & Johnson Wound
Management

FlexiGel Hydrogel Sheet
Dressing

Smith & Nephew

Aquacel Hydrofiber
Wound Dressing

ConvaTec

Optifoam Nonadhesive Dressing

Medline Industries

Tielle Hydropolymer Adhesive
Dressing

Johnson & Johnson Wound
Management

Allevyn Adhesive

Smith & Nephew

Modern

Alginate

Hydrogel

Foams
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Bioactive

Hydrocolloids

Semi-permeable

Anti-microbial

Biostep Collagen Matrix
Dressing

Smith & Nephew

Puracol Plus Collagen Dressings

Medline

Hyalomatrix

Anika Therapeutics

Duoderm CGF Sterile Dressing

Convatec

Replicare Thin Hydrocolloid
Dressing

Smith & Nephew

Bioclusive

Systagenix

Mefilm

AliMed

OpSite Plus

Smith & Nephew

Tegaderm

Johnson & Johnson Wound
Management

Acticoat absorbent

Smith & Nephew

Actisorb Silver 220

Johnson & Johnson Wound
Management

Aquacel AG

Convatec

Contreet H

Coloplast Corp

Contreet F

Coloplast Corp

Iodosorb

HealthPoint Ltd

Silvasorb Antimicrobial Silver
Dressing

Medline Industries

Kerlix and Gauze

Tyco Healthcare/Kendall

2.5.1. Alginates

Alginates is a type of polysaccharide dressing which has excellent absorbance properties
for wounds that create a high volume of exudate. They are salts of alginic acid polysaccharides
that form gels upon exudate absorption and can swell 15 to 20 times their weight which can be
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applied to wounds.44 Alginate also has had implications in wound healing where it induced
fibroblast proliferation and macrophage signaling of tumor necrosis factor (TNF-α).45, 46
Alginates are biocompatible and generally ideal for all stages of wound healing. However, they
require secondary dressings, need to be changed daily and are not ideal for dry wounds with little
exudate.31, 44
2.5.2. Hydrogels & foams

Hydrogels are non-toxic, inert cross-linked amorphous or elastic polymeric dressings that
are insoluble in aqueous media. They can be made of synthetic polymers such as
poly(methacrylates), polyvinylpyrrolidine or alginate based composites.31 Hydrogels provide
moisture to the wound site and can absorb a certain amount of exudate depending on its
composition. They also provide a non-adherent and cool surface that encourages wound
debridement and provides comfort to patients.31 Hydrogels are indicated for necrotic and sloughy
wounds.31, 44 Its drawback is it cannot absorb high amounts of exudate, otherwise leading to
infection.44 Additionally, they are mechanically weak, leading to constant dressing changes.
Hydrogels also typically require a secondary dressing to be held in place. Foam dressings are like
semipermeable films in that they are made of polyurethane plastics and have an occlusive
backing to prevent water loss and bacterial absorption; however, they are more absorbant.31 It is
more absorbent due to the foam’s pore size that allows a high moisture vapor transmission rate.47,
48

Foam dressings provide great insulation and have hydrophilic-hydrophobic layers which allow

optimal distribution of exudate within the dressing in addition to preventing leakage. Foam
dressings also come in thicker conformations to fill cavity like wounds.44 Foams, however do not
work well with dry wounds because these dressings require wound exudate to provide the
necessary moisture at the injury site.
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2.5.3. Bioactive dressings
Bioactive dressings are the most compatible of wound dressings because of their origin in
the human body, particularly extracellular matrix components in addition to actively playing a
role during the wound healing process. In literature, collagen, elastin, hyaluronic acid and
chitosan are natural biomaterials that have been explored as wound dressing materials.49-51 They
are biodegradable, do not illicit an immune response and directly assist in the wound healing
process. Collagen, for example induces clotting in the homeostasis phase while encouraging
fibroblast proliferation and endothelial cell recruitment to the wound site during the proliferation
stage.52, 53 Collagen sponges were reported to absorb exudate, debris and inflammatory cells from
the wound site.54 Hyaluronic acid, whose origin as a joint lubricant has been used as a carrier for
growth factor delivery in acute wound treatment.55 In more recent years, chitosan has received
attention as a potential wound dressing biomaterial as a study helped validate its ability to
accelerate granulation during the wound healing process.56
2.5.4. Hydrocolloids & semipermeable films

Hydrocolloid dressings are occlusive films or sheets made of materials such as
carboxymethylcellulose, gelatin and pectin which form a gel-like consistency upon adherence to
either dry or wet surfaces.44 They are water impermeable and usually have adhesive layers on the
perimeter of the dressing to maintain a moist wound environment.44 These dressings are
indicated for low and moderately exudating wounds and have been used to treat diabetic ulcers.31,
44

One disadvantage of hydrocolloid dressings is that their adhesive layer can prevent oxygen

exchange between the outside environment and the wound. Another problem is fiber residues
that remain in the wound bed have to be removed upon dressing change.31
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Semipermeable films are transparent layers made of polyurethane with an acrylic
adhesive backing which are highly flexible for application at joints, body contours and other hard
to reach areas.31, 44 They are impermeable to fluids but actively exchanges gases around the
wound site. Semipermeable films can only be used for low to moderately exudating wounds and
are not thick enough to fill cavity like wounds. 31, 44
2.6 Wound dressing therapeutics
Therapeutics have been added to wound dressings over the years to enhance patient
comfort and to help accelerate the wound healing process. Doxycycline is an antibiotic
therapeutic used to inhibit tissue degrading MMPs during chronic wound healing.57 It is a
tetracycline class of antibiotics that combats bacterial infections. It works by deactivating the
30S ribosomal subunit that would otherwise initiate translation of the destructive MMPs. As a
result, doxycycline prevents biofilm formation common in chronic wounds. In addition, this
antibiotic is active against E. coli, methicillin-resistant Staphylococcus aureus (MRSA),
respiratory and urinary tract infections.58
Antimicrobial dressings are important during the wound healing process because they
contain therapeutic agents which inhibit potential bacterial infections caused by acute tissue
injury, post-operative surgery or from more chronic, pathological states such as diabetes.31 Many
anti-microbial dressings are impregnated with silver, which broadly act against infections caused
by skin burns and wounds. Antimicrobial dressings have been used to help fight looming
infections after tissue injury, particularly in diabetic ulcers. Silver has been the traditional
antimicrobial agent to treat bacterial colonies such as Staphylococcus aureus and P.
aeruginosa.44 Its mechanism of action involves the influx of silver ions to the bacterial
cytoplasm, where they shut down enzyme activity and as a result, potassium ions leak out the
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cell.59 The released ions cause the cytoplasm to burst and destroy the cell wall, leading to
apoptosis. 59 Silver can only be applied locally but has been effective inhibiting bacterial growth
and its resistance.60 Commercially, silver sulfadiazine is widely popular as a topical
antimicrobial agent for skin wounds and burns. However, its spectrum of use should be limited
because of its cytotoxicity. Iodine complexes, povidone-iodine and cadexomer iodine have been
integrated into fabrics to improve wound healing due to its ability to inhibit microbe growth and
encouraging debridement of the wound site.44 Gentamycin and oflaxcin have been impregnated
into collagen and silicone substrates respectively to form antimicrobial dressings. 31
Antimicrobial dressings are excellent broad-spectrum acting materials due to its ability to
prevent systemic infections that could otherwise cause acute wounds to become necrotic and
evolve into a chronic state. Nonetheless, the amount of anti-microbials should be moderated and
treated locally to prevent systemic toxicity or bacterial resistance.
2.7 Electrospun polysaccharides: material properties & applications
Electrospinning was first patented by Anton Formhals in 1934 as a technique to create
non-woven fibers using a voltage gradient between the syringe tip and collecting mandrel.61
Specifically, the polymer solution ejected from the syringe tip has an applied charge given by the
high voltage power supply. The applied charge in the solution overcomes its surface tension to
create a jet which dries into fibers as it propels to the collecting mandrel to create a non-woven
fiber sheet. (Figure 2.5)
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Figure 2.5: Electrospinning scheme
Electrospun nanofibers are an attractive platform as a wound dressing material because of
its high surface to volume ratio and porosity to allow moisture and exudate transport between the
dressing and injury site.62 The high porosity of nanofiber dressings have shown to absorb more
wound exudate than film dressing formulations.63 In addition, the high porosity of nanofibers
provides an environment where cells can exchange oxygen and inhibit bacterial permeation at
the wound-nanofiber interface.62 Nanofiber wound dressings are highly flexible and can
conform to the shape of the wound because of the very fine fiber diameter. This provides better
patient compliance and comfort.62 Beyond the physical characteristics, nanofibers can express or
maintain biological functionality after integrating bioactive components such as therapeutics,
growth factors and antifungals to enhance the wound healing process.62 These bioactive agents
can be homogenously distributed within the nanofiber scaffold, unlike other wound dressing
formulations which compartmentalize the agents in separate layers. The nano-scale morphology
also can encourage cell attachment and proliferation at the fibers for extracellular matrix
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production.64, 65 The physical properties of electrospun fibers can be easily modulated by its
polymer, solvent and electrospinning setup parameters.64 This is summarized in Table 2.2.

Table 2.2 Parameters affecting physical properties of electrospun fibers. [66]
Polymer Properties

Solution Properties

Other properties

Molecular weight

Viscosity

Substrate properties

Molecular-weight distribution

Viscoelasticity

Solution Feed Rate

Glass-transition temperature

Concentration

Field strength

Solubility

Surface tension

Geometry of electrode(s)

Electrical conductivity

Vapor pressure of the solvent
Relative humidity

Polysaccharide biopolymers have become widely popular in wound dressing
development recently because of their natural abundance, biodegradability, non-toxicity,
biocompatibility, and anti-microbial properties.65, 67, 68 They are versatile polymers because their
material properties can be manipulated by molecular weight, charge and chemical composition.
They are found in plants, animals and microbial organisms.69 Polysaccharides such as
glycosaminogylcans (GAGs) or proteoglycans are also a component of the extracellular matrix
whose integrity is important during wound healing. Cellulose, alginate, heparin and hyaluronic
acid with additives or in multiple solvent systems have been successfully electrospun into
nanofibers.69 Meanwhile, chitosan and chitin have been blended with other biopolymers such as
collagen and gelatin into nanofibers to study their potential use as a wound dressing material.
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2.7.1. Alginate

Alginate is an anionically charged, water soluble polysaccharide derived from brown
seaweed. It is a linear copolymer made up of M (mannuronic acid) and G-block (guluronic acid)
monomers. The proportion of M and G-blocks can influence the physical properties of the
nanofiber.70 Alginate fibers with high M-block content exhibit fibers with high absorption
capacity but low mechanical strength. Meanwhile, alginate fibers with high G-block content are
much stronger but has lower fluid absorption capacity.70 Alginate is attractive as a wound
dressing because it is non-toxic, non-immunogenic and biocompatible.69 Shalumon et al. created
Alginate/PVA blended nanofibers with zinc oxide as an anti-bacterial wound dressing.71
However, its potential in electrospinning has not been fully realized because of existing
challenges to fabricate uniform, continuous fibers. This is due to low chain entanglement created
by negative charge repulsions and length of polymer chains within the alginate network.69, 72, 73
As a result, groups introduced other polymers to assist in electrospinning such as polyethylene
oxide (PEO), polyvinyl alcohol (PVA) and glycerol to neutralize the electrostatic repulsions
which help promote greater fiber entanglement.69
2.7.2. Chitosan

Chitosan is a positively charged polysaccharide derived from chitin present in
crustaceans’ sea shells.69 Chitosan is a deacetylated form of chitin due to the loss of an acetyl
group (-COCH3). It is soluble in acidic solutions (pH < 6) whose properties are dependent on the
polymer’s molecular weight, degree of acetylation and distribution of acetylation on the polymer
backbone.74, 75 Chitosan is a strong candidate as a wound dressing material because it is:
biocompatible, non-toxic, anti-microbial, biodegradable, hemostatic, and can be a substrate for
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cell attachment.76 Chitosan nanofibers can be a substrate for cell attachment because their
polymer structure is similar to glycosaminoglycans (GAGs) which are a major component of the
extracellular matrix.69 Unfortunately chitosan, like alginate is difficult to spin because of its
highly charged nature but there are a handful of solvents that can dissolve it into a solution that
can be successfully electrospun. Acetic acid (90 wt. %), trifluoroacetic acid (TFA) and
TFA/dichloromethane (DCM) are solvent systems typically used to electrospin chitosan.77
However, chitosan fibers lack stability in aqueous solutions and have limited electrospinning
conditions that can successfully form fibers so additional polymers are introduced to improve
spinnability such as PEO, PVA, collagen and silk.65, 68, 77, 78
2.7.3. Hyaluronic acid

Hyaluronic acid is a linear polysaccharide that is a major part of the extracellular matrix
in connective tissues.79 Hyaluronic acid is a quality wound dressing material for its
biocompatible and biodegradable properties. Hyaluronic acid (HA) has been reported to be
successfully electrospun in dimethylformamide and water.79 However, there has been limited
success electrospinning HA on its own due to its high charge density and surface tension. As a
result, blended co-polymers are needed for it to be consistently electrospun successfully. Gelatin,
PEO and zein, a corn protein have been blended with HA to form fibers. Ji et al. electrospun
hyaluronic acid derivatives into fibers as an ECM mimicking substrate favorable for NIH3T3
cell attachment and spreading which is ideal for tissue regeneration.80
2.8 Polysaccharide hydrogels: material properties & applications
Hydrogels are crosslinked networks that are very hydrophilic and absorb large amounts
of water without dissolving because of irreversible chemical or physical bonds that stabilize the
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gel.81 They are excellent platforms for wound dressing applications because they swell
significantly which helps with wound exudate absorption. Also, their hydrophilic properties
enable the hydrogel to keep the wound bed moist. Hydrogels have good bioadhesive properties
that assist with maintaining moisture at the wound site while potentially delivering
antimicrobials that may be integrated in the hydrogel for sustained action against infected
wounds. Hydrogels are very flexible and conform in a variety of conditions.82-85
The hydrogel’s material properties are dependent on: i) amount of fluid absorption and ii)
the nature of bonding within the crosslinked polymer chains.81 The more hydrophilic groups in
the hydrogel the greater swelling properties and vice versa. The bonding within crosslinked
hydrogels is between functional groups within the polymer chains that stabilize the gel from
dissolving.81 Hydrogel crosslinking can take place by either non-covalent crosslinks through
physical entanglement and secondary bonding or by covalent crosslinks.86, 87 Non-covalent
hydrogel crosslinking can reversibly take place while hydrogel crosslinking via covalent bonds is
permanent. As a result, the reversibility of the crosslinking reaction has a major influence on the
elasticity of the hydrogel’s swelling in solution. This swelling takes place through the expansion
of the polymer chains as aqueous solution rushes into the hydrogel. In reversible hydrogel
systems, its polymer chains constantly fluctuates in expansion and retraction while irreversible
systems undergo fluctuation until reaching a swelling equilibrium.88 The hydrogel’s surface
wettability, solute diffusion coefficient and mechanical properties are influenced by its swelling
equilibrium.89-91
Polymer properties such as molecular weight, charge and crosslinking density all play a
role in modulating the degree of swelling in aqueous solutions. Typically, hydrogels with high
molecular weights and crosslinking densities are stiff and rigid with high modulus values.92, 93
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Meanwhile, solute diffusion out of hydrogels are controlled by their crosslinking density, mesh
and pore sizes.94, 95 Polysaccharides in hydrogel formulations have been used in many
applications because they are highly versatile, complex polymers that are readily available and
can be easily manipulated into gels. They are natural, non-toxic while exhibiting
immunomodulatory properties.96 Polysaccharide hydrogels have been predominantly used as
drug delivery carriers but are gaining traction as tissue engineering scaffolds because of the
similar structure it has to the extracellular matrix. A variety of polysaccharides have been used
for tissue engineering and drug delivery such as alginate, gellan, dextran, hyaluronic acid and
etc.97 There are also countless therapeutics that have been integrated into polysaccharide
hydrogels to enhance application. Although there has been an explosion of papers in literature
that have reported on the uses of polysaccharide hydrogels in drug delivery and tissue
engineering, there is a gap in research regarding their potential applications as wound dressing
materials.
2.8.1. Alginate
Alginate is an anionically charged, water soluble polysaccharide derived from brown
seaweed. 70 It is widely used because of its fast ability to form gels. This is due to the carboxylic
acid moieties on the alginate chain interacting with di-valently charged ions such as calcium,
lead and copper which initiate crosslinking.97 The material properties of alginate can be modified
by changing the ratio of its M-block (mannuronic acid) and G-block (guluronic acid) monomers.
Alginate hydrogels with high M-block content have high fluid absorption capacity but low
mechanical strength. Conversely, hydrogels with high G-block content have high strength but
low water absorption capacity. 70 Alginate hydrogels have potential as wound dressing materials
because they form stable hydrogels while exhibiting biocompatibility, non-immunogenicity and
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porosity for fluid absorption. 97 Alginate hydrogels are considered candidates of wound dressing
materials because of its ability to form an in-situ hydrogel in calcium ions present in wound
exudate.98 Balakrishan et al. completed a series of studies where alginate, gelatin and anti-septic
borax were incorporated into an in-situ forming hydrogel for wound healing applications.99-101
2.8.2. Chitosan
Chitosan is a linear polysaccharide β 1-4 linked D-glucosamine and N-acetyl-Dglucosamine units. It is produced by the deacetylation of its parent polymer chitin and is often
found in shells of shrimp and crab. Chitosan is different from other polysaccharides by the
presence of nitrogen atoms, its cationic charge and ability to form polyelectrolyte complexes. 81
They are good candidates as wound dressing materials because they are biocompatible, non-toxic
and biodegradable. They are highly conformable and come in many shapes and sizes.85
These hydrogels are fabricated via physical mixture or crosslinks to create a structured network.
Chitosan hydrogels can be physically mixed into stable networks by introducing anionic ions or
macromolecules to neutralize the positively charged chitosan and induce electrostatic attraction
within the gelatinized network. Secondary bonding, hydrophobic-hydrophilic interactions and
thermoresponsive gelation can also take place in chitosan hydrogels depending on what
monomers or catalysts are added to it.81 While this method is non-toxic, the issue with physical
crosslinking is the lack of long term stability and should only be used for short-term applications.
Chemical crosslinking of chitosan hydrogels is straightforward using either small molecules,
light, enzyme catalysts or polymers to create more stable networks. However, this crosslinking
method is more toxic because of the by-products created from the reaction. 81
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Figure 2.6: Chemical structure of chitosan

Chitosan has been used as a wound dressing material because of its ability to protect the
wound while being biocompatible and providing moisture to the wound environment. It has been
shown that chitosan accelerates wound healing and promotes smooth scarring due to enhanced
vascularization and a high supply of chittooligomers that incorporate collagen fibrils more
efficiently at the extracellular matrix.102, 103 Important wound healing mediator fibroblast growth
factor (FGF-2) has been successfully integrated into chitosan hydrogels. It maintained its
bioactivity after impregnation into the chitosan hydrogel.51 Park et al. developed bFGF-loaded
chitosan hydrogels to accelerate wound repair in chronic ulcers.104
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2.8.3. Dextran
Dextran is a glucose homopolysaccharide that is primarily used as a protein drug delivery
system because their sustained release kinetics improve the protein’s bioavailability compared to
being free in circulation.97 Dextran can be crosslinked physically by gamma irradiation to
provide greater stability in the network. The stability of the dextran hydrogel is controlled by the
length of irradiation and dextranase levels in the system which hydrolytically degrades the
scaffold. The proteins trapped inside the dextran hydrogel have Fickian diffusion release kinetics
in aqueous solution because they are much smaller than the pore sizes in the network that allow
proteins to travel from an area of high concentration to low concentration. 97 Dextran hydrogels
are relevant as potential wound dressing materials because anti-microbials can be introduced
whose release is controlled by matrix metalloproteases active at the wound site. They have also
exhibited angiogenesis and promotion of complete skin healing in animal burn wound models.105
Sun et al. created excisions to full-thickness wounds before dextran hydrogel scaffolds were
implanted with a secondary dressing layer for up to 21 days. 105 The study showed complete
dermal regeneration after implantation of dextran hydrogels compared to non-treated and treated
control groups. (Figure 2.7)
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Figure 2.7: Evaluation of regenerated skin structures. (A) Quantification of skin structures in
terms of dermal differentiation (i), epithelial maturation (ii), and the number of hair follicles (iii).
(B) A 5-week-long study further demonstrated that dextran hydrogels promote complete skin
regeneration with new hair growth, as shown by photos (arrows indicate the center of the original
wound; Upper) and H&E-stained histologic sections. High magnification corresponds to boxed
area in the low-magnification images. (C) Quantification of skin thickness after 3-week and 5week-long treatment compared to normal mouse skin. Significance levels were set at: *p < 0.05,
**p < 0.01, and ***p < 0.001. Values shown are means ± SD. Scale bars, 100 μm. (from ref[105]
with permission)
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2.8.4. Gellan
Gellan gum is a polysaccharide derived from Sphingomonas elodea bacterium
fermentation. Gellan, like alginate forms gels when mixed with divalent ions. Its mechanical
strength is dependent on the degree of acylated groups. 97 The more acylated groups, the more
soft and elastic the gel is while deacylated gellan hydrogels are stiff and non-elastic. Although
gellan has primarily been explored as ocular, nasal and drug delivery carriers, more recent work
has been done to evaluate gellan as a silver impregnated wound dressing.106-109 Nonetheless,
gellan gum is still in an early stage of being evaluated solely as a wound dressing.

Figure 2.8: Average structures and/or repeating units of gellan

2.8.5. Hyaluronic acid
Hyaluronic acid is a glycosaminoglycan composed of repeating disaccharide units of Dglucuronic acid and N-acetylglucosamine.110 It is a large component of the extracellular matrix,
particularly in connective tissues. Also, it is viscoelastic, highly biocompatible, nonimmunogenic and biodegradable which makes it appealing as a hydrogel formulated wound
dressing. 97 Hyaluronic acid forms hydrogels upon crosslinking with use of glutaraldehyde and 134

Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) reagents.111 One group used hyaluronic
acid functionalized with adipic dihydrazide and crosslinked with poly-ethylene glycol (PEG)
propriondialdehyde to create a film which successfully delivered anti-microbial and antiinflammatory agents in vitro, showing promise as a wound dressing.112 Others have combined
hyaluronic acid with agarose or fibronectin to create hydrogels which also could potentially be
used as a wound dressing material.113, 114
2.8.6. Arabinoxylan

Arabinoxylan (AX) is a neutral non-starch polysaccharide derived from cereal grains
such as wheat.1 They are water extractable and are comprised of a xylose backbone substituted
onto arabinose units. Arabinoxylan ferulate (AXF) is arabinoxylan with ferulic acid substituted
onto its arabinose monomer. (Figure 2.9) AXF can be readily cross-linked with oxidative
reagents peroxidase and hydrogen peroxide. They function by creating an ester bond between
ferulic acid and arabinose units to form a dimer which crosslinks the arabinoxylan chains
together.115 Cross-linked arabinoxylan gels have high water absorption capacity which allows for
potential drug delivery applications of therapeutics such as albumin and ibuprofen.1, 116
Experiments have shown arabinoxylan hydrogels to have a two and a half fold increase in
swelling when introduced into water.115 This phenomenon was attributed to its honeycomb
shaped pores and hydrophilic properties as a lyophilized hydrogel. Arabinoxylan also does not
require the use of toxic organic solvents but uses water instead for solubilization.
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Figure 2.9: Arabinoxylan ferulate structure. Arabinoxylan ferulate (AXF) is composed of three
components: A) xylose backbone substituted to B) arabinose sugar units, one of which is
substituted to C) ferulic acid.
Arabinoxylan polysaccharides have many benefits outside of its material properties.
Arabinoxylan has shown potential as a drug delivery system as a gel by exhibiting high protein
release. The rate of release can be modulated by the initial amount of protein loaded into the
gel.1As a lyophilized hydrogel, it has relatively large pore sizes ranging from 200 to 400
nanometers which allow the proteins to be introduced into without any significant damage to the
protein.1 In addition, the flexibility of arabinoxylan chains enables fluid and solute movement in
and out of the delivery system based on the gel’s degree of crosslinking.1 Studies have also
shown arabinoxylan to regulate the lining of the gastrointestinal system.1, 117 Clinical studies with
diabetes implications have shown arabinoxylan’s ability to modulate gut metabolism affecting
glucose levels downstream.118, 119 Last, arabinoxylan has been integrated with other natural
polymers such as alginate and gelatin to form fiber meshed wound dressings.70
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2.9 Conclusions
Polysaccharides have been primarily used in food, textile or cosmetic products but their
potential as wound dressings is vast because of their abundant, non-toxic, biocompatibility and
non-immunogenic properties in physiological systems. They also are excellent candidates
because they are structurally diverse in their molecular weight and chemical structure which in
turn influences the overall material properties. Many of the polysaccharides described in this
review have demonstrated their applicability in the laboratory in vitro and in vivo. However,
these class of polymers are still considered niche bioactive wound dressings commercially. We
hope this review will encourage research groups to further explore polysaccharides and
appreciate its value within the wound dressing market.
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Abstract:
Research strategies in developing polysaccharide carbohydrate biomaterials for wound
healing have steadily grown over the last decade. Arabinoxylan (AX) is a carbohydrate polymer
derived from cereal grains. However, its potential for clinical applications has yet to be fully
realized. Arabinoxylan ferulate (AXF), a type of arabinoxylan is hydrophilic and possesses
tunable swelling properties for wound fluid absorption. This study aims to demonstrate the
feasibility of electrospinning AXF to fibers and investigate the physical and biocompatible
properties of the resulting nanofiber constructs. Gelatin (GEL) was blended with AXF to
facilitate fiber formation and provide a natural polymer that host tissues can readily accept after
injury. Blends of GEL and AXF at 1:1, 2:1 and 4:1 ratios were successfully electrospun and
characterized in terms of morphology, tensile properties, pore size and molecular composition.
Fiber diameter increased with respect to polymer concentration (0.425, 0.586 and 1.09 µm for
1:1, 2:1 and 4:1 GEL-AXF blends respectively). Moduli values for 1:1, 2:1 and 4:1 GEL-AXF
blends were 6.3, 22.9 and 46.0 MPa respectively, indicative of the greater strength with respect
to polymer concentration. In addition, the scaffold possessed excellent cytocompatibility
(fibroblast cell viability > 95%). Silver was impregnated into GEL-AXF nanofibers at 5% w/w
concentration to enhance its anti-microbial properties against wound pathogens. After integration
of silver, the drug exhibited near zero-order release kinetics with 20.9, 17.0 and 10.6%
cumulative drug release for 1:1, 2:1 and 4:1 GEL-AXF blends respectively after 48 hours. Silver
release from the scaffolds also inhibited bacterial growth as confirmed by disk-diffusion assay.
This work shows electrospun GEL-AXF fibers are biocompatible and have tunable material
properties. However, its stability in water needs to be improved with co-electrospinning with
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more stable polymers to achieve the potential of this novel scaffold for wound dressing
development.
Keywords: gelatin, electrospinning, nanofiber, arabinoxylan, wound dressing
3.1 Introduction
Electrospun fibers are an attractive platform as wound dressing materials because of its
high surface to volume ratio, porosity, conformity at the wound site and ease of fabrication. 120
The properties of electrospun fibers can be easily manipulated by the polymer concentration,
flow rate, voltage and air gap distance. Electrospun polysaccharide polymers have become
widely popular in wound dressing development recently because of their natural abundance,
biodegradability, non-toxicity, biocompatibility, and anti-microbial properties.65, 67, 68 They are
versatile polymers because their material properties can be manipulated by molecular weight,
charge and chemical composition. Polysaccharides such as glycosaminogylcans (GAGs) or
proteoglycans are play a role in the extracellular matrix as a substrate for cell migration and
attachment during the proliferative phase of wound healing. They are found in plants, animals
and microbial organisms.69 Polysaccharides such as cellulose, alginate, heparin, chitosan and
hyaluronic acid combined with additives or in multiple solvent systems have been successfully
electrospun into nanofibers.69
Arabinoxylan (AX) is a polysaccharide biopolymer containing a xylose backbone with
arabinose substituted in the O-2 or O-3 positions of the backbone.1 The xylose and arabinose
units are linked together by ester linkages which makes AX hydrophilic. The applications of
arabinoxylan range from packaging materials, as prebiotics to regulate gut metabolism to fiber
meshes.70, 119, 121AX’s hydrophilic and absorbent properties allows for moisture exchange
between the wound dressing and wound.115 However, little work has been done to explore AX as
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an electrospun wound dressing material despite many of the aforementioned strengths. Like
other polysaccharides, AX cannot be electrospun solely due to the polymeric backbone’s
repulsive charges reducing chain entanglement. In this study, arabinoxylan ferulate (AXF)
blended with gelatin produced novel, co-electrospun fiber mats that are highly porous, exhibit
tensile strength, are biocompatible and can exhibit anti-microbial properties after integration with
silver sulfadiazine. The results suggest there is potential of this biomaterial in advanced wound
dressing development.

A

B

C

Figure 3.1: Arabinoxylan ferulate structure. AXF is composed of three components: A) xylose
backbone substituted to B) arabinose sugar units, one of which is substituted to C) ferulic acid.
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3.2 Materials and methods
3.2.1. Materials
Arabinoxylan ferulate (AXF) was purchased from Cambridge Biopolymers (Cambridge,
UK). Porcine type-A gelatin, Total Carbohydrate Assay Kit, 70% Nitric Acid, Silver (I)
Sulfadiazine were purchased from Sigma-Aldrich (St. Louis, MO). 1,1,1,3,3,3-hexafluoro-2propanol (HFP) was purchased from TCI America (Portland, OR). Phosphate buffered saline
(PBS) was purchased from EMD Chemicals (Gibbstown, NJ). Dulbecco’s modification of
eagle’s medium (DMEM) was purchased from Invitrogen (Carlsbad, CA). Fetal calf serum was
purchased from Lonza (Walkersville, MD). Hyclone 0.05% Trypsin was purchased from Thermo
Scientific. (Logan, UT) Penicillin Streptomycin was purchased from Life Technologies. (Grand
Island, NY). Sulfuric Acid was purchased from Fisher Scientific (Pittsburgh, PA).
3.2.2. Scaffold preparation

Preparation of GEL-AXF nanofiber blends involved two steps: homogenization and
electrospinning.
3.2.2.1. Preparation of electrospinning solution

A mass of 250 milligrams of AXF was added to 10 mL of HFP. The mixture was
homogenized for five minutes to break down particles in the solvent. Next, 250, 500 and 1000
mg of gelatin were quickly added to the resulting mixture. The resulting mixtures led to 1:1, 2:1
and 4:1 GEL-AXF mixtures respectively. The vials were placed on a shaker plate and shaken
continuously overnight.
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Figure 3.2: Schematic of GEL-AXF electrospinning solution preparation

3.2.2.2. Preparation of silver-loaded GEL-AXF electrospinning solution

To create 1:1, 2:1 and 4:1 GEL-AXF blends with 5% w/w silver sulfadiazine, 30, 40 and
70 milligrams of silver sulfadiazine was added with 250 milligrams of arabinoxylan in HFP
before homogenization. (Table 3.1) This concentration of silver in the GEL-AXF blends was
used to be equivalent to the amount in the 3M Alginate commercialized wound dressing
containing an ionic silver complex made of silver, sodium, hydrogen, zirconium and
phosphate.122, 123 After homogenization, 250, 500 and 1000 milligrams of gelatin was added to
the resulting mixture and placed on a shaker plate overnight.
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Table 3.1 Preparation of silver loaded GEL-AXF scaffolds
Formulation

GEL (mg)

AXF (mg)

Silver sulfadiazine (mg)

1:1 GEL-AXF
2:1 GEL-AXF
4:1 GEL-AXF

250
500
1000

250
250
250

30
40
70

3.2.2.3. Preparation of GEL-AXF scaffolds

To fabricate electrospun gelatin fibers, the GEL-AXF solution was drawn up through the
blunted needle (18G×1½ in) of a 10 ml syringe. The syringe was loaded into a syringe pump,
propelling the gelatin solution out of the needle 150 mm away from the collecting mandrel at a
rate of 5 ml/hr for 4:1 and 2:1 blends. The flow rate was decreased to 2 ml/hr for 1:1 blends
because the solution would otherwise bead at 5 ml/hr. The needle was connected to a positive
electrode of a high voltage power supply (Spellman CZE100R, Spellman High Voltage
Electronics Corporation). The positive electrode applied a 20 kV voltage to the needle. This
voltage created an electric field opposite to the grounded target to overcome the surface tension
at the needle tip. These conditions generated a Taylor cone which allowed a steady stream of
gelatin solution to flow from the needle to the grounded collecting plate in a jet-like fashion. As
the GEL-AXF solution was being streamed from the needle tip, the HFP solvent evaporated.
Randomly aligned nanofibers were collected on a flat, stainless steel mandrel (7.5 cm×2.5
cm×0.5 cm, L× W×T) rotating at 500 rpm. Scaffolds were sterilized by UV light for ten minutes
on each side.

44

syringe

polymer solution

Needle – 18 G x ½ in

collecting mandrel – ~ 500 rpm
fibers
Air gap distance – 150 mm
syringe pump
1:1 GEL-AXF – 2 ml/h
2:1 and 4:1 GEL-AXF – 5 ml/h

High Voltage Power Supply – 20 kV

Figure 3.3: Electrospinning setup and conditions.
3.2.2.4. Crosslinking of GEL-AXF scaffolds

GEL-AXF electrospun scaffolds were immersed in approximately 500 μl of 1% w/v
PEG-Diacrylate and 10% w/v Eosin-Y photoinitiator solution per 100 mg of scaffold before 10
minute UV light treatment for each side of the scaffold.
3.2.3. Scanning electron microscopy (SEM)
Prior to SEM imaging, scaffolds were placed on a 1 cm diameter stub. The stub was
placed on a specimen holder and platinum sputter coated. SEM images were taken and analyzed
under JEOL JSM-5610LV Scanning Electron Microscope. One hundred randomly chosen fibers
and their pores in each SEM images were analyzed with UTHSCSA ImageToolTM software for
fiber diameter and pore size measurement.
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3.2.4. Tensile testing
“Dog-bone” shaped samples (n=12) were obtained using a punch die (ODC Testing &
Molds) of the dimensions 19.0, 3.2 and 6.1 mm at its length, narrowest point and widest point,
respectively.124 Mechanical properties of the samples, including peak load, peak stress, modulus,
strain at break and energy to break, were tested using the MTS Bionix 200 Mechanical Testing
System in conjunction with TestWorks 4.0 software.
3.2.5. Carbohydrate assay
The entire electrospun 1:1, 2:1 and 4:1 Gel-AXF blends were weighed with their masses
recorded.124 Then the mats were dissolved in 10 mL of PBS. Based on their corresponding
concentrations, the dissolved mats were diluted to 2.5 mg/mL. 2 mg/mL concentration of glucose
standards in the carbohydrate assay kit produced by Sigma Aldrich (St. Louis, MO) were used to
reference the sample concentrations. A 20 µL microliter aliquot was taken out of 1:1, 2:1 and 4:1
GEL-AXF 2.5 mg/mL stock solutions and added to a 96 well plate in five replicates before being
filled to a 50 µL volume with de-ionized water. Next, 150 µL of sulfuric acid was added to each
well and incubated in a water bath at 90◦C for 15 minutes. After cooling down, 30 µL developer
solution from the assay kit is added to each well that is placed on a horizontal shaker plate for 5
minutes. After shaking, the plate is read at 490 nm for quantitative spectrophotometric
measurement to confirm the presence of arabinoxylan in the scaffolds after electrospinning.
3.2.6. Drug release kinetics studies
One half of the electrospun 1:1, 2:1 and 4:1 Gel-AXF blends impregnated with silver
sulfadiazine was weighed with their masses recorded. The scaffolds were immersed in a conical
flask containing 20 mL of 2% nitric acid solution. At 1 hr, 2 hr, 6 hr, 12 hr, 24 hr and 48 hr time46

points, a 5 mL aliquot of release media was taken out and collected into a 15 mL centrifuge tube.
The sample aliquots were then analyzed for silver release quantification by ICP-OES. Intensity
measurements for silver were calibrated against a standard curve to estimate silver concentration
values which were then converted to mass. Triplicate samples were independently measured
twice for the study.
3.2.7. WST-1 cell viability assay

The entire electrospun 1:1, 2:1 and 4:1 GEL-AXF blends were weighed with their masses
and concentrations recorded. Next, they were sterilized with 1000 ppm peracetic acid for 15
minutes and washed in PBS three times for 10 minutes using the protocol developed by
Yoganarasimha et al.125 The sterilized fibers were centrifuged for five minutes at 3000 rpm.
Afterwards the fibers was dissolved in DMEM and 10% PBS for 15 minutes to a stock
concentration of 25 mg/mL. The treatment medium was centrifuged again for five minutes at
3000 rpm before collecting the supernatant which was serially diluted to 5, 0.5, 0.05 mg/mL with
pure DMEM serving as a control. NIH3T3 fibroblasts were seeded at a density of 10,000 cells
per well in 96 well plates then 200 µL of the degradation media was added. The cells were
incubated with the degradation media for 24 hours at 37◦C and 5% CO2. After incubation, the
seeded cells were given 100 µL of fresh DMEM media before adding 10 µL of WST-1 reagent.
The cells were incubated for one hour before the plate is read spectrophotometrically at 450 nm.
Relative cell activities from treated groups were measured by taking their absorbance
measurements and normalizing them versus absorbance values from untreated control groups.
WST-1 assay works through the reagent salt, tetrazolium being cleaved into a dark red formazan
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dye whose intensity can be quantified. The salt cleavage is due to mitochondrial enzymes
produced by metabolically active cells whose proliferation and viability correlate colormetrically.
3.2.8. Trypan blue cell viability & proliferation assay
The same preparation procedures were done for these electrospun blends as in Section
3.2.7. before treating the cells with the prepared degradation media. After preparation, NIH3T3
fibroblasts were seeded at a density of 50,000 cells per well in a 24 well plate before 500 µL of
the degradation media was added. The cells were incubated with the degradation media for 24
hours at 37◦C and 5% CO2. After incubation, the seeded cells were trypsinized with and
suspended in 1:1 trypsin-DMEM solution before centrifugation for five minutes at 3000 rpm.
After centrifugation, the supernatant was aspirated and the cell pellet was re-suspended in a 1:1
mixture of PBS-trypan blue dye for five minutes before 20 µL aliquots were taken out to
measure viability and cell number.
3.2.9. Kirby-Bauer disk diffusion assessment
The Kirby-Bauer Disk Diffusion susceptibility test determines bacterial antibiotic
susceptibility or resistance based on the size of its inhibition zone.126 Pseudomonas aeruginosa,
Staphylococcus aureus and Enterococcus faecalis were subject bacteria in this study because of
their occurrence being the three most frequent bacteria species in an epidemiology study on
patients with post-surgical wound infections.127 Five microliter frozen aliquots of gram-positive
bacterial species Staphylococcus aureus and Enterococcus faecalis were cultured in BHI broth
media for 18 hours at 37◦C. Gram-negative strain Pseudomonas aeruginosa was cultured in LB
broth media for 18 hours at 37◦C. S. aureus and P. aeruginosa were cultured in a standard
incubator shaking at 200 rpm while E. faecalis was incubated in a 6% oxygen Anoxomat jar. All
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species were cultured overnight to a concentration of approximately 1-2 x 109 CFU/mL after
incubation.
After incubation, a sterile cotton swab was inoculated in each of the cultures and spread
on agar medium in a 100 mm Petri dish and allowed to dry for five minutes. After drying, 6 mm
diameter filter paper samples impregnated with a known concentration of antibiotic for the test
organism was used as a positive control. Representative 6 mm diameter 4:1 GEL-AXF fibers
impregnated with silver sulfadiazine and negative control 4:1 GEL-AXF fibers without silver
sulfadiazine were placed in the remaining two quadrants on the agar. (Table 3.2) The Petri
dishes containing samples inoculated with S. aureus and P. aeruginosa were stored in a standard
incubator for 24 hours. Petri dishes containing test samples of E. faecalis were incubated in a 6%
oxygen Anoxomat jar for 24 hours. After incubation, top and bottom images of the Petri dishes
were acquired using a digital camera and image processing software (Photo/AnalystR PC Image,
Fotodyne, Inc.). The growth inhibition zones diameters were measured manually with a caliper.
Disk diffusion susceptibility testing was performed twice under the same conditions on different
days. The mean of the inhibition zone diameters of each treatment were then determined.
Table 3.2 Kirby-Bauer susceptibility test setup

Bacterial
Species (Strain)

Positive Control
(Antibiotic)

Treatment

Negative Control
(no treatment)

Pseudomonas
aeruginosa (PAO1)

Tetracycline; 30 µg

4:1 GEL-AXF fibers
w/ 5% silver
sulfadiazine

4:1 GEL-AXF fibers w/o
silver sulfadiazine

Staphylococcus
aureus (RN450)

Erythromycin; 15 µg

4:1 GEL-AXF fibers
w/ 5% silver
sulfadiazine

4:1 GEL-AXF fibers w/o
silver sulfadiazine

Enterococcus
faecalis (V583)

Tetracycline; 30 µg

4:1 GEL-AXF fibers
w/ 5% silver
sulfadiazine

4:1 GEL-AXF fibers w/o
silver sulfadiazine
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3.2.10. Statistical analysis
Statistical analysis was carried out using an unpaired t-test and one way analysis of
variance (ANOVA) with post-hoc analysis for subgroup comparison. P values less than 0.05
were considered statistically significant.
3.3 Results and discussion
3.3.1. Fiber morphology, diameter and pore size

Uniform and random aligned fiber morphology were seen in all uncrosslinked GEL-AXF
blends. Fiber diameter and pore size increased with respect to gelatin concentration. The 1:1, 2:1
and 4:1 GEL-AXF blends have fiber diameters of 425 nm, 586 nm and 1.09 µm respectively.
(Figure 3.5) Meanwhile, the pore sizes for 1:1, 2:1 and 4:1 Gel-AXF blended fibers are 0.66, 1.4
and 3.6 µm2 respectively. (Figure 3.5) This data suggest that the electrospun mat’s pore sizes
increase with respect to higher GEL-AXF blends because their larger fiber diameter reduces the
number of intersecting points which creates larger void spaces within the mat. Another possible
reason that fiber diameter and pore size correspondingly increase with gelatin concentration is
the 2 ml/hr flow rate for 1:1 GEL-AXF blends propel less polymer out of the syringe compared
to 5 ml/hr flow rates for 2:1 and 4:1 GEL-AXF blends.
Ethanol and tri-ethanolamine were used to dissolve crosslinking reagents, PEG-DA and
Eosin Y before crosslinking the electrospun mat. The scaffolds completely lost their morphology
after the crosslinking step. This was attributed to the hydrophilicity of gelatin and arabinoxylan
which created fiber fusion in their mats. Scaffold shrinkage also took place after crosslinking. As
a result, the fiber diameter and pore size could not be measured quantitatively.
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3.10.2 Tensile Testing

Figure 3.4: SEM of GEL-AXF scaffolds. A) 1:1 GEL-AXF blend; B) 2:1 GEL-AXF blend; C)
4:1 GEL-AXF blend; D) 1:1 GEL-AXF blend with crosslinker; E) 2:1 GEL-AXF blend with
crosslinker; F) 4:1 GEL-AXF blend with crosslinker.
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Figure 3.5: Fiber diameter & pore size of GEL-AXF blended scaffolds (n = 100)
A) Fiber Diameter; B) Pore Size (*p < 0.05; significant differences among each of 1:1, 2:1 and
4:1 GEL-AXF groups tested vs. each other)
3.3.2. Tensile testing
Uncrosslinked GEL-AXF nanofibers had moduli values of 6.3, 22.9 and 46.0 MPa for 1:1,
2:1 and 4:1 GEL-AXF blends respectively. (Table 3.3). It was also clear that peak load and peak
stress increased in proportion to amount of gelatin blended into the fibers. Meanwhile, strain at
break decreased with respect to gelatin blended. Due to strain being inversely proportional to
modulus, the higher moduli values for GEL-AXF blends with greater amounts of gelatin
possessed lower strain values. Crosslinked 1:1, 2:1 and 4:1 GEL-AXF fibers had moduli values
of 1.00, 3.10 and 2.00 MPa respectively. Although peak load and peak stress increased in
proportion to gelatin, it was not as pronounced when compared to uncrosslinked GEL-AXF
scaffolds. No correlation between GEL-AXF blend ratios and modulus was present in
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crosslinked scaffolds. (Table 3.4) This is possibly due to the crosslinker changing the original
thickness of the scaffold which directly relates to modulus as shown for uncrosslinked scaffolds.
Table 3.3 Mechanical properties of uncrosslinked GEL-AXF scaffolds (n =12)
GEL-AXF
Blend Ratio

Thickness
(in)

Peak Load (N)

Peak Stress
(MPa)

Modulus
(MPa)

Strain At
Break
(mm/mm)

Energy to
Break
(N*mm)

1:1

0.0084 ±
0.00133

0.29 ± 0.093

0.50 ± 0.16

6.3 ± 2.2

0.14 ± 0.056

0.15 ± 0.071

2:1

0.011 ±
0.0015

0.59 ± 0.16

0.77 ± 0.19

23.0 ± 9.3

0.075 ± 0.040

0.12 ± 0.031

4:1

0.017 ±
0.00077

1.4 ± 0.18

1.2 ± 0.15

46.0 ± 5.7

0.033 ±
0.0069

0.17 ± 0.049

Table 3.4 Mechanical properties of crosslinked GEL-AXF scaffolds (n = 12)
GEL-AXF
Blend Ratio

Thickness
(in)

Peak Load
(N)

Peak Stress
(MPa)

Modulus
(MPa)

Strain At
Break
(mm/mm)

Energy to
Break
(N*mm)

1:1

0.001 ±
0.0023

1.2 ± 0.56

1.80 ± 0.62

1.1 ± 0.28

2.2 ± 0.38

9.8 ± 5.8

2:1

0.015 ±
0.0065

2.2 ± 1.1

2.3 ± 0.63

3.1 ± 2.3

1.9 ± 0.64

16 ± 8.9

4:1

0.013 ±
0.0049

2.8 ± 0.83

3.3 ± 1.19

2.0 ± 0.92

2.2 ± 0.33

23 ± 7.9
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3.3.3. Carbohydrate assay
Overall, arabinoxylan was present in all of the electrospun 1:1, 2:1 and 4:1 GEL-AXF
blends, with 11%, 4% and 2% of arabinoxylan in the entire scaffold respectively. (Figure 3.6)
The 1:1 GEL-AXF blend had a greater absolute proportion of arabinoxylan amount remaining
compared to other blends. However, the 1:1 GEL-AXF blend lost a significantly greater
proportion of arabinoxylan during electrospinning than the 2:1 and 4:1 blends. Meanwhile, the
GEL-AXF 4:1 blend lost a significantly smaller proportion of arabinoxylan during
electrospinning than the 2:1 and 1:1 blends. (Figure 3.7) This is attributed to the ability of
gelatin and its ability to be electrospun and capture arabinoxylan particles at higher
concentrations such as the 4:1 GEL-AXF blend. A greater proportion of arabinoxylan is left
behind during electrospinning for 1:1 and 2:1 GEL-AXF blends where the gelatin concentrations
are lower and less suitable to generate fibers on the mandrel.
Carbohydrate Assay: Amount of Arabinoxylan in Scaffold

Arabinoxylan Percentage in Scaffold

18
16

*

14
12
10
8
6
4
2
0
GEL-AXF 1-1

GEL-AXF 2-1

GEL-AXF 4-1

Blend

Figure 3.6: AXF percentage in scaffold after electrospinning (n = 10) (*p < 0.05; significant
difference for 1:1 GEL-AXF group vs. 2:1 and 4:1 GEL-AXF groups)
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Carbohydrate Assay: Difference of Arabinoxylan proportion
before and after electrospinning
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Arabinoxylan Loss in Scaffold (%)

p < 0.05
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GEL-AXF 1-1
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GEL-AXF 4-1
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Figure 3.7: AXF loss percentage in GEL-AXF scaffold after electrospinning (n = 10) (*p < 0.05;
significant differences among each of 1:1, 2:1 and 4:1 GEL-AXF groups tested vs. each other)
3.3.4. Silver release kinetics
Overall, the release rate of each of the silver loaded GEL-AXF blended nanofiber
scaffolds was similar over the 48 hour time course. (Figure 3.8) There was an initial burst
release within the first two hours before following more controlled kinetics afterwards,
characteristic of zero-order kinetics. In the first two hours, the 1:1 and 2:1 GEL-AXF blended
nanofiber scaffolds possessed a significantly greater cumulative silver release of 8.49 and 7.29%
than the 4:1 GEL-AXF blend which released 4.19% silver. After two hours, only the 1:1 GELAXF blend had a significantly greater percent cumulative release than the 4:1 blend. After 48
hours, 1:1, 2:1 and 4:1 GEL-AXF impregnated with silver had 20.9, 17.0 and 10.6% cumulative
release respectively. This phenomenon is likely due to the greater density of gelatin nanofibers in
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4:1 GEL-AXF blends encapsulating the silver longer before release. Also, the greater density of
gelatin reduced bulk degradation within the scaffold which slowed release of the encapsulated
silver.
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Figure 3.8: Cumulative silver sulfadiazine release from 1:1, 2:1 and 4:1 blended GEL-AXF
scaffolds over a 48 hour period. (n = 6) (*p < 0.05; significant differences among 1:1 GEL-AXF
vs. 2:1 and 4:1 GEL-AXF groups at denoted times) (**p < 0.05; significant differences among
1:1 GEL-AXF vs. 4:1 GEL-AXF at denoted times.)

3.3.5. WST-1 assay for cell viability
After 24 hours, all treatment groups containing degradation media produced greater cell
activity values than control groups containing plain DMEM. Cell activity steadily increased with
respect to concentration of 2:1 and 4:1 GEL-AXF blends up to 1.77 and 1.64 fold respectively
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until 25 mg/mL where it slightly declined to 1.67 and 1.38 fold. Meanwhile, 1:1 GEL-AXF
blends induced greater cell activity for all concentration values, ranging from 1.08 to 2.25 fold at
0.05 and 25 mg/mL respectively. (Figure 3.9) The presence of arabinoxylan may have induced
greater cell activity compared to control treatments and with respect to its blend ratio with
gelatin. This could be indicative of arabinoxylan’s naturally derived origin promoting
biocompatibility in the cell microenvironment. Overall, arabinoxylan electrospun in gelatin
nanofiber scaffolds encouraged cell activity and was not cytotoxic to fibroblasts which play a
key role in tissue matrix regeneration and wound healing.

3.5
0.05 mg/mL
0.5 mg/mL
5 mg/mL
25 mg/mL

p < 0.05
p < 0.05

3.0

Relative Cell Viability

p < 0.05
2.5

2.0

1.5

1.0

0.5

0.0
GEL-AXF 1:1 blend

GEL-AXF 2:1 blend

GEL-AXF 4:1 blend

Blend

Figure 3.9: Relative cell activity of NIH3T3 cells with respect to GEL-AXF blend ratio and
concentration after 24 hour incubation period. (n = 8) (*p < 0.05; significant differences among
denoted 1:1, 2:1 and 4:1 GEL-AXF groups)
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3.3.6. Trypan blue cell viability & proliferation assay
Introduction of arabinoxylan into electrospun gelatin did not have a cytotoxic effect on
NIH3T3 fibroblast cells. Fibroblasts possessed viability percentages of at least 94.7% after
treatment with degradation media from 1:1, 2:1 and 4:1 GEL-AXF blended fibers for 24 hours.
(Figure 3.10) No significant differences were found in percent viability with respect to GELAXF blend ratio. Fibroblasts treated with degradation media from 1:1 GEL-AXF, 2:1 and 4:1
fibers had viability percentages ranging from 94.5 to 98.6%, 97.1 to 98.4% and 94.6 to 97.7%
respectively. Non-treated fibroblasts were 97.8% viable after 24 hour incubation in DMEM +10%
FBS. There were no statistically significant differences among blended fibers with respect to
degradation media concentration.
GEL-AXF fibers also had a positive effect on fibroblast proliferation as the cell number
doubled from 50,000 to 100,000 after 24 hour incubation for all treatments with exception to 25
mg/ml concentration of 2:1 GEL-AXF blend. The grey dotted line in (Figure 3.11) illustrates the
doubling mark of 100,000 cells. No significant differences were found in percent viability with
respect to GEL-AXF blend ratio. Fibroblasts treated with degradation media from 1:1 GEL-AXF
fibers had cell numbers increase with respect to concentration, reaching a peak of 142,000 cells
at 5 mg/mL before declining to 125,000 at 25 mg/mL. Fibroblasts treated with degradation media
from 2:1 and 4:1 fiber blends also exhibited a similar trend reaching a peak cell number of
155,000 and 151,000 before falling to 73,500 and 110,000 respectively. Non-treated fibroblasts
proliferated to 101,000 after 24 hour incubation in DMEM +10% FBS. Despite the high cell
viability numbers for fibroblasts treated with 25 mg/mL concentrations of 1:1, 2:1 and 4:1 blend
ratios of GEL-AXF, the lower cell proliferation numbers at this concentration may be attributed
to a material dosing effect where the cell activity is hindered by the scaffold. Nonetheless, there
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were no statistically significant differences among blended fibers with respect to degradation
media concentration.
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Figure 3.10: Viability of NIH3T3 fibroblast cells with respect to GEL-AXF blend ratio and
concentration after 24 hour incubation period. (n = 8)
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Figure 3.11: Cell number of NIH3T3 fibroblasts with respect to GEL-AXF blend ratio and
concentration after 24 hour incubation period. (n = 8)
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3.3.7. Kirby-Bauer disk diffusion assessment
GEL-AXF fibers were assessed for their anti-microbial activity by measuring the
inhibition zones within each species of bacteria. P. aeruginosa was highly susceptible to silver
sulfadiazine impregnated 4:1 GEL-AXF fibers, which actively inhibited bacterial growth with an
inhibition zone of 16.24±1.43 mm, greater than the inhibition zone of the tetracycline positive
control. The effectiveness of silver sulfadiazine was consistent to previous data showing its
applicability in a skin wound models.128 Gram-positive S. aureus and E. faecalis species were
less sensitive to the silver sulfadiazine impregnated 4:1 GEL-AXF fibers with an inhibition zone
diameter of 9.51 ± 0.37 and 9.39 ± 0.54 mm respectively. One possible reason that these species
showed some resistance compared to gram-negative P. aeruginosa is that gram-positive bacteria
are more susceptible to antibiotics and have a thicker cell wall that make it more difficult to
break down.129 All three species of bacteria were sensitive to 4:1 GEL-AXF fibers impregnated
with silver sulfadiazine. P. aeruginosa was most susceptible to the silver impregnated fibers
among the three species. All three positive control treatments achieved clear inhibition of each of
the bacterial species after 24 hour incubation. (Figure 3.12) As expected, all bacterial species
grew and showed resistance to 4:1 GEL-AXF fibers with no silver sulfadiazine. The growth
inhibition data from two trials are also summarized in Table 3.5.
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P. aeruginosa G(-)

S. aureus G(+)

A

A
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B

B

A
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E. faecalis G(+)

C

B

B

A

C

B

C

Figure 3.12: Antimicrobial properties of 4:1 GEO-AXF fiber mats using Kirby-Bauer disk
diffusion susceptibility test on gram negative G(-) and gram positive G(+) bacteria. Tetracycline
(A), Silver sulfadiazine impregnated 4:1 GEL-AXF fibers (B) and 4:1 GEL-AXF fibers (C) were
tested on Pseudomonas aeruginosa and Enterococcus faecalis bacterial species. Erythromycin
(A), Silver sulfadiazine impregnated 4:1 GEL-AXF fibers (B) and GEL-AXF fibers (C) were
tested on Staphylococcus aureus bacterial strain. (n = 2)
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Table 3.5 Sensitivity profiles of bacterial species after treatment

Species

Treatment

Average inhibition zone (mm)

Positive Control
(30 µg Tetracycline)

15.38±0.53

4:1 GEL-AXF fibers w/
5% silver sulfadiazine

16.24 ±1.43

Negative Control
(no treatment)

0

Positive Control
(15 µg Erythromycin)

23.83 ±0.55

4:1 GEL-AXF fibers w/
5% silver sulfadiazine

9.51 ±0.37

Negative Control
(no treatment)

0

Positive Control
(30 µg Tetracycline)

28.25 ±1.06

4:1 GEL-AXF fibers w/
5% silver sulfadiazine

9.39 ±0.54

Negative Control
(no treatment)

0

P. aeruginosa

S. aureus

E. faecalis
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3.4 Conclusions
Synthesis of blended GEL-AXF electrospun nanofibers was successful. Addition of
gelatin increased fiber diameter and the pore size of the scaffold. In turn, this increased the
scaffold’s elastic modulus. Crosslinker reagents were formulated to help stabilize the scaffold
but the results indicate reduced surface morphology and mechanical strength. Arabinoxylan was
successfully integrated into the gelatin nanofibers and has potential to act as a wound dressing.
However, the degradation profile indicated the uncrosslinked and crosslinked GEL-AXF scaffold
disintegrated within 30 minutes in aqueous media (data not shown). Arabinoxylan should be
incorporated with a more stable polymer such as polylactic acid (PLA) or polylactic-co-glycolic
acid (PLGA) to reduce scaffold degradation in media.130 In vitro biocompatibility results were
promising as fibroblast cell viability and proliferation were the same or greater than non-treated
groups. Silver impregnated GEL-AXF fibers exhibited antimicrobial activity against bacterial
pathogens. In future testing, GEL-AXF fibers will be implanted onto an injury site of an animal
model where in vivo drug release and tissue viability will assess the drug delivery and
biocompatibility properties. The host immune response after foam implantation in vivo will be
examined by measuring at neutrophil count or pro-inflammatory cytokines in affected biopsy
wounds. Electrospun GEL-AXF fibers are good platforms as wound dressing materials because
of their high surface to volume ratio, abundance, their naturally derived origin and their
absorptive capacity. This study hopes to exhibit the feasibility and efficacy of fabricating novel
electrospun arabinoxylan based fibers in an effort to advance wound dressing development.
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Abstract:
Fabrication of a functional wound dressing material is critical in managing wound
healing. Traditional wound dressings such as gauze achieve the minimum by simply protecting
and covering the wound. More advanced wound dressings aim to achieve greater functionality by
absorbing wound exudate to keep the wound site moist and preventing biofilm formation. Many
current advanced wound dressing materials on the market possess the aforementioned properties
but none have used arabinoxylan (AX) as a base material. AX should be considered as a wound
dressing because of its absorptive properties and naturally derived origin. It is also inexpensive.
The goal of this study is to investigate and highlight the material and biocompatible properties of
Arabinoxylan ferulate (AXF) foams as a potential wound dressing material. To achieve this goal,
the AXF foam’s material properties such as morphology, storage modulus, porosity, swelling
and cumulative drug release kinetics were examined. Endotoxin quantification, fibroblast activity
and microbial growth inhibition studies were completed to test the in vitro biocompatibility of
AXF foams. Tegaderm Alginate foam dressings manufactured by 3M were included in many of
these studies for comparison. The in vitro results indicate that AXF foams are highly porous,
absorptive scaffolds which have swelling ratios over 20 times its original weight. AXF foams are
non-toxic to the cell microenvironment, exhibiting cell viabilities over 95% and cell numbers
doubling after 72 hours. Silver (5% w/w) was successfully integrated into AXF foams and
achieved 45% cumulative release after 48 hours in vitro. Silver impregnated AXF foams also
inhibited bacterial lawn growth using a modified Kirby-Bauer disk-diffusion method. Overall,
AXF foams possess many appropriate material properties necessary to be a candidate material in
wound dressing development.
Keywords: wound dressing, foam, arabinoxylan, wound management, biopolymer, crosslinking
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4.1 Introduction
Wound dressing development is important in clinical settings because of the emphasis to
improve the rate of wound healing while preventing threatening infections after injury. Medical
device manufacturers are advancing wound dressing features beyond what is already exhibited in
traditional dressings such as gauze. Those types of wound dressings are expected to primarily
protect the wound from further injury. Advanced wound dressings are expected to keep the
wound site moist, absorb wound exudate, remove the wound odor, prevent biofilm formation and
encourage skin regeneration in addition to the features described of traditional wound
dressings.33, 34 It should also have good biocompatibility. It should have appropriate mechanical
strength for insulation, wound protection and exudate removal from the injury site. Lastly, it is
expected be absorptive, impermeable to bacteria and inexpensive. 31, 43
Polysaccharide polymers have been used as advanced wound dressings because they are
natural, highly abundant, biodegradable and non-toxic. They also have components that are
recognized by the body and play a role in rebuilding the extracellular matrix.131 Polysaccharides
can be crosslinked to form gels that are highly absorbent that keep the wound bed moist.132 They
are candidates as wound dressing materials because of their ability to carry and deliver drugs in a
controlled fashion. Alginate, chitin, chitosan, hyaluronan and heparin are examples of
polysaccharides that have been used as commercially wound dressings.131
Arabinoxylan (AX) is a polysaccharide containing a xylose backbone with arabinose
substituted in the O-2 or O-3 positions of the backbone.1 The xylose and arabinose units are
linked together by ester linkages which gives the biopolymer its hydrophilic properties. Ferulic
acid can be coupled to arabinoxylan via ester linkages to produce the resulting Arabinoxylan
ferulate (AXF). AXF in water can be crosslinked to form gels by radical polymerization to create
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dimers at the ester bond between ferulic acid and the arabinose unit.115 The applications of
polysaccharides related to AX range from packaging materials to prebiotics that regulate gut
metabolism.70, 119, 121 More specifically, AX gels have been developed by several groups as
delivery systems which have proven to deliver therapeutics such as methyl xanthine and albumin
in vitro.1, 115 AX gel fabrication is very simple, does not require use of harsh organic solvents and
its mechanical properties can be tuned with respect to the crosslinking density. Arabinoxylan has
an ability to swell and absorb liquids because of its hydrophilic properties.115 In this study,
lyophilized AXF foams will be fabricated then characterized to evaluate their material properties,
and biocompatibility to evaluate its potential as a wound dressing.
4.2 Materials and methods
4.2.1. Materials
Arabinoxylan ferulate (AXF) was purchased from Cambridge Biopolymers (Cambridge,
UK). Horseradish peroxidase and 35% wt. hydrogen peroxide were purchased from SigmaAldrich (St. Louis, MO). 1,1,1,3,3,3-hexafluoro-2-propanol (HFP) was purchased from TCI
America (Portland, OR). Phosphate buffered saline (PBS) was purchased from EMD Chemicals
(Gibbstown, NJ). Dulbecco’s modification of eagle’s medium (DMEM) was purchased from
Invitrogen (Carlsbad, CA). Fetal calf serum was purchased from Lonza (Walkersville, MD).
Hyclone 0.05% Trypsin was purchased from Thermo Scientific (Logan, UT). Penicillin
Streptomycin was purchased from Life Technologies (Grand Island, NY). Tegaderm Alginate
and Ag Tegaderm Alginate was purchased from 3M Health Care (St. Paul, MN). LAL
Chromogenic Endotoxin Quantitation Kit was purchased from Thermo Scientific (Rockford, IL).
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4.2.2. Scaffold preparation
4.2.2.1. Preparation of arabinoxylan foams

Two batches of 600 milligrams of AXF dry powder were added to two 10 milliliter
aliquots of deionized water, stirred and shaken until dissolved. Next, 50 µl of 1 mg/mL solution
of peroxidase and 60 µl of (3% w/v) hydrogen peroxide was added to each of the reaction
mixtures and stirred to initiate enzymatic crosslinking.133 (Figure 4.1) Immediately, the solutions
were poured together into a 100 mm Petri-dish before sonication for 30 minutes. After sonication,
the crosslinked solutions were set in room temperature for three hours to cure. After curing, the
crosslinked gel was freeze-dried overnight to produce the final product. 3MTM Tegaderm
Alginate foam dressing served as an established commercialized peer for comparison.

Figure 4.1: Diagram of enzymatic crosslinking of arabinoxylan ferulate (AXF) in solution. The
ferulic acid group of AXF ( ) crosslinked with the arabinose sugar of arabinoxylan ( ) via
horseradish peroxidase (HRP) and hydrogen peroxide (H2O2) to form a hydrogel network on the
xylose backbone (
).
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4.2.2.2. Preparation of silver-loaded arabinoxylan foams

To create AXF foams with 5% w/w concentration of silver, approximately 65 milligrams
of silver sulfadiazine was added with 600 milligrams of AXF in deionized water before stirring.
After stirring, the procedure was followed from Section 4.2.1. Ag 3MTM Tegaderm Alginate
foam dressing with 5% silver served as an established commercialized peer for comparison. This
concentration of silver in the GEL-AXF blends was equivalent to the amount in the Alginate
wound dressing that contained an ionic silver complex made of silver, sodium, hydrogen,
zirconium and phosphate.122, 123
4.2.3. Morphology
Prior to SEM imaging, scaffolds were placed on a 1 cm diameter stub. The stub was
placed on a specimen holder and platinum sputter coated. SEM images were taken and analyzed
under JEOL JSM-5610LV Scanning Electron Microscope to see any distinguishing features in
the surface morphology of the scaffolds.
4.2.4. Rheology
Rheological testing was performed on samples and cut into 10 mm diameter disks.
Testing was performed on dry and wet samples on a temperature controlled plate of a Discovery
Hybrid Rheometer. Wet samples were immersed in 1 mL of phosphate buffer saline (PBS) for
one hour before blot drying. Each set of samples on the plate at 25 and 37 degrees Celsius were
under compression, undergoing shear stress by an 8 mm diameter probe. The parameters for the
compression probe were as follows: 500 µm gap size, 0.1-100 Hz frequency and 0.1% strain rate
during the measurement. These settings derived from the work done by Zuidema et al.134 This
study was done in duplicate.
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4.2.5. Swelling ratio
The sample was cut into 10 mm diameter disks by biopsy punch then weighed to record
their masses. Next, they were immersed in 1.5 mL of PBS at room temperature for seven days
and taken out at pre-determined time points (6h, 12h, 24h, 48h, 72h and 168h). At each time
point, the swollen foam was taken out, blot dried and re-weighed to record its mass. The swelling
ratio was calculated by the following formula:
Swelling Ratio = [(Wf/Wa)] x 100
Where Wf = final mass of sample, and Wi = initial mass
This study was done in duplicate.
4.2.6. Drug release kinetics
Samples were cut into 10 mm diameter disks then incubated in 20 mL of 2% Nitric acid
solution at 37 degrees. The mass of silver sulfadiazine in the scaffold was estimated by taking 5%
of the scaffolds mass. The foams were immersed in a conical flask containing 20 mL of 2%
Nitric acid solution. At 1 hr, 2 hr, 6 hr, 12 hr, 24 hr and 48 hr time-points, a 5 mL aliquot of
release media was taken out and collected into a 15 mL centrifuge tube. The sample aliquots
were then analyzed for silver release quantification using ICP-OES. Intensity measurements for
silver were calibrated against a standard curve to estimate silver concentration values which were
then converted to mass. Triplicate samples were independently measured twice for the study.
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4.2.7. Limulus amebocyte lysate (LAL) endotoxin assay
The AXF foams were weighed then sterilized with 1000 ppm peracetic acid for 15
minutes and washed in PBS three times for 10 minutes using the protocol developed by
Yoganarasimha et al.125 The sterilized AXF foams were air-dried for 10 minutes and along with
unsterile foams, were placed into tissue culture inserts for each well. The inserts containing the
foam samples were immersed in PBS for four hours. After immersion, a 50 µl aliquot was
extracted from the release media and diluted 20-fold with addition of 1 mL of endotoxin free
media from the endotoxin assay kit. After dilution, 50 µl aliquots were taken from the diluted
samples and added to a 96-well plate. Next, 50 µl of LAL reagent was added to the sample for
10 minute incubation at 37◦C. Afterwards, 100 µl of chromogenic substrate was added to the
reaction mixture and incubated for six minutes at 37◦C to induce colormetric reaction based on
protease enzyme activity induced by the endotoxin. A 50 µl aliquot of 25% acetic acid was
added to end the reaction before samples were gently shaken before spectrophotometric
measurement at 405 nm.
4.2.8. Trypan blue cell viability & proliferation assay

The AXF foams were sterilized with 1000 ppm peracetic acid for 15 minutes and washed
in PBS three times for 10 minutes using the protocol developed by Yoganarasimha et al.125 The
sterilized AXF foams were air-dried for 10 minutes and placed into tissue culture inserts which
were immersed into individual wells. NIH3T3 fibroblasts were seeded at a density of 50,000
cells per well in a 12 well plate before the inserts were introduced. The cells were incubated with
the scaffold containing inserts for 24 and 72 hours at 37◦C and 5% CO2. After incubation, the
seeded cells were trypsinized with and suspended in 1:1 trypsin-DMEM mixture before
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centrifugation for five minutes at 3000 rpm. After centrifugation, the supernatant was aspirated
and the cell pellet was re-suspended in a 1:1 mixture of PBS-trypan blue dye for five minutes
before 20 µL aliquots were taken out to measure viability and cell number. 3M Alginate foams
were used for commercial scaffold comparison while no scaffold served as a control treatment.
4.2.9. Kirby-Bauer disk diffusion assessment
The Kirby-Bauer Disk Diffusion susceptibility test determined bacterial antibiotic
susceptibility or resistance based on the size of its inhibition zone.126 Pseudomonas aeruginosa,
Staphylococcus aureus and Enterococcus faecalis were subject bacteria in this study because of
their occurrence being the three most frequent bacteria species in an epidemiology study on
patients with post-surgical wound infections.127 Five microliter frozen aliquots of gram-positive
bacterial species Staphylococcus aureus and Enterococcus faecalis were cultured in BHI broth
media for 18 hours at 37◦C. Gram-negative strain Pseudomonas aeruginosa was cultured in LB
broth media for 18 hours at 37◦C. S. aureus and P. aeruginosa were cultured in a standard
incubator shaking at 200 rpm while E. faecalis was incubated in a 6% oxygen Anoxomat jar. All
species were cultured overnight to a concentration of approximately 1-2 x 109 CFU/mL after
incubation.
After incubation, a cotton swab was inoculated in each of the cultures and spread on agar
medium in a 100 mm Petri dish and allowed to dry for five minutes. After drying, 6 mm diameter
samples impregnated with a known concentration of antibiotic for the test organism was used as
a positive control. AXF foams impregnated with silver sulfadiazine, Alginate foam impregnated
with silver and AXF foams without silver were placed in the remaining three quadrants on the
agar. (Table 4.1) The Petri dishes containing samples inoculated with S. aureus and P.
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aeruginosa were stored in a standard incubator for 24 hours. Petri dishes containing test samples
of E. faecalis were incubated in a 6% oxygen Anoxomat jar for 24 hours. After incubation, top
and bottom images of the petri dishes were acquired using a digital camera and image processing
software (Photo/AnalystR PC Image, Fotodyne, Inc.). The growth inhibition zones diameters
were measured manually with a caliper. Disk diffusion susceptibility testing was performed
twice under the same conditions on different days. The mean of the inhibition zone diameters of
each treatment were then determined.

Table 4.1 Kirby-Bauer susceptibility test setup

Bacterial
Species (Strain)

Positive Control
(Antibiotic)

Treatment 1

Treatment 2

Negative Control
(no treatment)

Pseudomonas
aeruginosa (PAO1)

Tetracycline; 30 µg

AXF foam w/
5% silver
sulfadiazine

ALG foam
w/5% silver

AXF foam w/o silver
sulfadiazine

Staphylococcus
aureus (RN450)

Erythromycin; 15 µg

AXF foam w/
5% silver
sulfadiazine

ALG foam
w/5% silver

AXF foam w/o silver
sulfadiazine

Enterococcus
faecalis (V583)

Tetracycline; 30 µg

AXF foam w/
5% silver
sulfadiazine

ALG foam
w/5% silver

AXF foam w/o silver
sulfadiazine

4.2.10. Statistical analysis
Statistical analysis was carried out using an unpaired t-test and one way analysis of
variance (ANOVA) with post-hoc analysis for subgroup comparison. P values less than 0.05
were considered statistically significant.
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4.3 Results and discussion
4.3.1. Morphology

The AXF foams exhibited a porous, smooth morphology which allows high fluid
absorption. Also, the pores were in the micro scale and evenly distributed along the surface
which encouraged fluid absorption and drug release. Meanwhile, the 3M Alginate foams
possessed a smooth surface with a random entanglement of microfibers. The porous structure
was less ordered which may affect fluid absorption but not significant enough to dry out the
wound bed. (Figure 4.2)

A

B

C

D

Figure 4.2: SEM images of A) 3M Alginate at 500 µm; B) 3M Alginate at 100 µm; C) AXF
foam at 500 µm; D) AXF foam at 100 µm.
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4.3.2. Rheology
The AXF foams had significantly higher storage modulus values than 3M Alginate foams
in the dry state at both 25 and 37 degrees Celsius. (Figure 4.3) The storage modulus for dry 3M
Alginate foams across 0.1-100 Hz frequencies was 2.58-4.07 MPa. Meanwhile, the storage
modulus for AXF foams at 25 degrees Celsius was 30.6-52.2 MPa. At 37 degrees Celsius, 3M
Alginate foams and AXF foams had storage moduli of 2.40-3.86 and 24.8-25.9 MPa respectively
over the same frequency range. This phenomenon was attributed to the greater stiffness and
viscosity in the dry AXF foams. Hydrated 3M Alginate and AXF foams at 25 degrees Celsius
exhibited storage moduli of 0.256-1.62 and 0.005-0.792 MPa across 0.1-100 Hz frequency range,
respectively. Hydrated 3M Alginate and AXF foams at 37 degrees have storage modulus values
of 0.242-1.48 and 0.006-0.822 MPa across the same frequency range respectively. The results
suggested hydrated AXF foams to some extent lost some stiffness and were more viscous than
elastic. In the hydrated state, 3M Alginate foams had significantly higher storage modulus values
than AXF foams because AXF is a hydrophilic polymer that swells significantly when hydrated.
As a result, the polymer chains in the foam expanded which compromised its elasticity and
strength. Overall, the storage modulus of the AXF and Alginate foams were lowered by three
and one order of magnitude respectively after they were hydrated. (Figure 4.4)
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Figure 4.3: Storage modulus of dry AXF and 3M alginate foams under shear stress at A) 25 and
B) 37 degrees Celsius. (n = 16) (*p < 0.05; significant differences of AXF foam vs. 3M Alginate
foam at both temperatures)
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Figure 4.4: Storage modulus of hydrated AXF and 3M alginate foams under shear stress at A)
25 and B) 37 degrees Celsius. (n = 16) (*p < 0.05; significant differences of AXF foam vs. 3M
Alginate foam at both temperatures)
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4.3.3. Swelling ratio
Overall, both scaffolds had high swelling capacities because of their porous morphology.
The swelling ratios of 3M Alginate at 25 degrees Celsius were 670% at six hours to a final
swelling ratio of 1703% after 168 hours. AXF foams had a six hour swelling ratio of 1432% at
six hours and 2145% after 168 hours. Meanwhile at 37 degrees, 3M Alginate foams possessed a
six hour swelling ratio of 930% that swelled to a 1096% after 168 hours. AXF foams at 37
degrees had swollen 1302% then reaching 2025% after 168 hours. Both scaffolds swell rapidly
within the first 12 hours before reaching a plateau at 24 hours. (Figure 4.5) The AXF foam
exhibited a significantly higher swelling ratio than 3M Alginate foams during the 168 hour time
period. This is because AXF is highly water absorbent which increases in mass after being
immersed in water. AXF foams also have a tendency to retain fluid much more than its 3M
Alginate counterparts due to its inelasticity within the polymer network.
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Figure 4.5: Swelling ratio of AXF and 3M alginate foams immersed in PBS at A) 25 and B)
37◦C. (n = 5) (*p < 0.05; significant differences of AXF foam vs. 3M Alginate foam at both
temperatures)

4.3.4. Drug release kinetics studies
AXF foams released 12% of silver sulfadiazine by weight in the first hour, and continued
to linearly release silver over the study’s time course to give a final cumulative silver release of
44% after 72 hours. (Figure 4.6) The amount of cumulative silver sulfadiazine release from AXF
foams was much higher than the 3M Alginate foam. This was most likely attributed to initial
swelling, bulk degradation and erosion of the AXF foam in comparison to Alginate foams. Like
many polysaccharide based materials, AXF’s hydrophilicity causes aqueous medium to penetrate
and cause the foam to swell significantly and allow silver to diffuse out quickly. Subsequently,
the foam’s polymer chains became loosened, leading to a loss of its integrity and drug solute
transport.135 The amount of silver sulfadiazine released from the 3M Alginate foam was below
the limit of quantification threshold during ICP-OES analysis. This may be due to the dressing
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being designed for very slow release and being less hydrophilic than AXF foams. The initial
burst release of silver sulfadiazine out of AXF foams is expected to inhibit microbes at the
wound site which will prevent further inflammation, biofilm formation and the wound from
transitioning into the chronic state. However, because the cumulative silver sulfadiazine release
becomes linear after the burst effect at 1 hr, it is important to analyze the cytotoxicity of the
silver sulfadiazine impregnated AXF foams over an extended period of time. Silver in excessive
amounts kill healthy cells in addition to microbes.
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Figure 4.6: Cumulative silver sulfadiazine release from AXF foam. (n = 6)
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4.3.6. Limulus amebocyte lysate (LAL) endotoxin assay
LAL Endotoxin levels for unsterilized and sterilized AXF foams were 5.30 ± 1.10 and
3.42 ± 0.87 EU/mg respectively, showing a 35.6% reduction after treatment. (Figure 4.7) The
Food and Drug Administration does not have a uniform endotoxin level limit for wound dressing
materials. However, it is imperative to minimize endotoxins to reduce symptoms such as fever
and septic shock. The reduction of endotoxins after peracetic acid sterilization helped contribute
to making AXF foams less cytotoxic and maintain baseline cell viability and proliferation in
vitro.
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Figure 4.7: LAL endotoxin content in AXF foams before and after sterilization. (n = 8) (*p <
0.05; significant difference of sterilized AXF foam compared to unsterilized AXF foam)
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4.3.7. Trypan blue cell viability & proliferation assay
The introduction of AXF foams into the in vitro microenvironment did not have a
cytotoxic effect on NIH3T3 fibroblasts. Their viability values were 96.6 and 96.4% over a 24
and 72 hour time period respectively. After exposure to the Alginate foam, fibroblasts were 96.7
and 97.3% viable after 24 and 72 hours. Untreated fibroblasts showed viability values of 95.8
and 96.9% after 24 and 72 hours. (Figure 4.8) There were no significant differences in viability
between AXF foams, Alginate foams and non-treated test groups. Based on the results, it can be
concluded that fibroblasts, which play a prominent role in the proliferative and remodeling stages
of wound healing were not negatively affected by exposure to AXF foams as their viability
maintained baseline levels.
Fibroblast proliferation after exposure to AXF foams was encouraging partly due to their
high viability in vitro. After incubation with an initial cell seeding density of 50,000 cells per
well, fibroblast cell number increased to 166,000 and 212,000 after 24 and 72 hours respectively.
Fibroblasts cultured with Alginate foams proliferated from 50,000 to 129,000 and 302,000 cells
per well after 24 and 72 hours respectively. (Figure 4.9) Meanwhile, non-treated test groups had
cell numbers of 205,000 and 289,000 cells per well after 24 and 72 hours respectively. There
were significant differences in cell number between 0 and 72 hour time-points for all treatment
groups.
The results summarized the biocompatibility and bio-inert properties of AXF foams. In
fact, they had proliferative inducing effects as they have greater cell numbers than Alginate and
non-treated groups after the first 24 hours. However, they were not statistically significant for
that time period. Another insight from the data was the lower cell number for AXF foam treated
fibroblasts compared to Alginate and non-treated groups after 72 hours. This was most likely
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attributed to the highly absorptive, hydrophilic properties of AXF foams as they absorbed
important growth factors (i.e. FGF) or intracellular signals necessary for fibroblast proliferation.
However, there were no significant differences with respect to treatment group for the 72 hour
incubation period.
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Figure 4.8: Cell viability of NIH3T3 fibroblast cells after exposure to alginate and AXF foams
after 24 and 72 hour incubation period. (n = 8)
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Figure 4.9: Cell proliferation of NIH3T3 fibroblast cells after exposure to 3M Alginate and
AXF foams after 24 and 72 hour incubation period. (n = 8) (*p < 0.05; significant differences in
cell number at 24 hours compared to cell number at 72 hours for all treatments)
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4.3.8. Kirby-Bauer disk diffusion assessment
The four treatment groups were assessed for their anti-microbial activity by measuring
the inhibition zones within each species of bacteria. P. aeruginosa was highly susceptible to
silver sulfadiazine impregnated AXF foams, which actively inhibited bacterial growth with an
inhibition zone of 22.17±1.53 mm, greater than the inhibition zone of the tetracycline positive
control. The effectiveness of silver sulfadiazine was consistent with previous data in literature
showing its applicability in a skin wound model.128 Gram-positive S. aureus and E. faecalis
species were less sensitive to the silver sulfadiazine impregnated AXF foams with an inhibition
zone diameter of 12.39 ± 1.26 and 12.32 ± 0.81 mm respectively. One possible reason that these
species showed some resistance compared to gram-negative P. aeruginosa is that gram-positive
bacteria are more susceptible to antibiotics and have a thick cell wall difficult to break down.129
All three species of bacteria were sensitive to AXF foams impregnated with silver
sulfadiazine. P. aeruginosa was most susceptible to the silver impregnated AXF foams among
the three species. For Alginate foams, the bacteria were more resistant with lower inhibition zone
diameters than silver impregnated AXF foams. In fact, E. faecalis was completely resistant to
silver impregnated Alginate foam. Irregularly shaped inhibition zones for silver impregnated
AXF foams against P. aeruginosa were due to the scaffold melting during incubation. All three
positive control treatments achieved clear inhibition of the three species after 24 hour incubation.
(Figure 4.10) As expected, all bacterial species grew and showed resistance to AXF foams with
no silver sulfadiazine. The growth inhibition data from two trials were summarized in Table 4.2.
The results suggest anti-microbials such as silver integrated into AXF foams can be successfully
delivered to the site of infections. In the future, more specific bacteria susceptible antibiotics can
be integrated in the AXF foam to improve efficacy. Combinations of antibiotics and silver could
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be combined together to create an anti-microbial cocktail to treat against infections. However,
the antibiotic selected is important as there is a wide array of bacteria species that is not
susceptible to the same antibiotic, possibly developing resistance and other complications at the
wound site.

Pseudomonas aeruginosa G(-)

Staphylococcus aureus G(+)
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Figure 4.10: Antimicrobial properties of 3M alginate and AXF foams using Kirby-Bauer disk
diffusion susceptibility test on gram negative G(-) and gram positive G(+) bacteria. Tetracycline
(A), Silver sulfadiazine impregnated AXF foams (B), AXF foams (C) and silver impregnated 3M
Alginate foams (D) were tested on Pseudomonas aeruginosa and Enterococcus faecalis bacterial
species. Erythromycin (A), Silver sulfadiazine impregnated AXF foams (B), AXF foams (C) and
silver impregnated 3M Alginate foams (D) were tested on Staphylococcus aureus bacterial strain.
(n = 2)
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Table 4.2 Sensitivity profiles of bacterial species after treatment
Species
P. aeruginosa

Treatment

Average inhibition zone (mm)

Positive Control
(30 µg Tetracycline)

14.40±5.44

AXF foam w/ 5% silver
sulfadiazine

22.17±1.53

ALG foam w/ 5% silver

10.04±1.82

Negative Control
(no treatment)

0

Positive Control
(15 µg Erythromycin)

23.02 ±0.59

AXF foam w/ 5% silver
sulfadiazine

12.39 ±1.26

ALG foam w/ 5% silver

5.75 ±0

Negative Control
(no treatment)

0

Positive Control
(30 µg Tetracycline)

27.62 ±0.16

AXF foam w/ 5% silver
sulfadiazine

12.32 ±0.81

ALG foam w/ 5% silver

0

Negative Control
(no treatment)

0

S. aureus

E. faecalis
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4.4. Conclusions
AXF foams are highly porous, biocompatible scaffolds that have a potential niche in the
market as a polysaccharide based wound dressing because it is inexpensive, easy to fabricate and
has material properties that are beneficial in wound healing. In this pre-clinical study, AXF
foams possessed higher swelling capabilities and compared to 3M Alginate foams
commercialized in the market. In their dry state, AXF foams also had higher mechanical strength
as its storage modulus was greater than for 3M Alginate foams. AXF foams can be impregnated
with silver which can be released in moist wound environments. However, more work needs to
be done to improve the mechanical stability of the scaffold in aqueous environments. A more
stable polysaccharide such as chitosan can be introduced to decrease the scaffold’s degradation
in solution. Additionally, a greater concentration of crosslinker can be used to strengthen the
polymer network. Processing conditions such as AXF gel freezing temperature and
lyophilization pressure will need to be explored to examine its effect on its material properties.
In the future, in vivo tests such as wound closure rate, in vivo drug release, and host immune
response should be done to validate the foam’s healing properties in injury and pathogenic
wound conditions. This work hopes to bring arabinoxylan polysaccharides to the forefront as a
biopolymer wound dressing that can be applied for treatment of wounds.

89

CHAPTER 5: Summary & future work
5.1 Summary
This dissertation aims to be the first to influence the biomaterials community to
investigate arabinoxylan as a wound dressing material. Arabinoxylan should be investigated as a
wound dressing material because of its high absorbency and hydrophilicity which absorbs wound
exudate. Arabinoxylan is naturally derived and biocompatible to not elicit a cytotoxic or foreign
body immune response. Arabinoxylan is also abundant and inexpensive which makes fabrication
cost-effective. Lastly, arabinoxylan can be successfully integrated with other polymers or in a
variety of formulations. Arabinoxylan can also be impregnated with anti-microbial drugs that can
be delivered to prevent wound infections.

5.1.1. GEL-AXF fibers
Arabinoxylan was successfully fabricated and characterized as a nanofiber scaffold after
being electrospun with different amounts of gelatin. GEL-AXF electrospun scaffolds possessed a
well-defined fiber morphology tunable from the nano and micro scales. GEL-AXF fibers also
possessed large pores to allow nutrient and oxygen exchange between the wound bed and
scaffold. Increased gelatin concentration in these blended fibers improved the mechanical
properties of the scaffold. However, when the scaffold was exposed in aqueous environments, it
was prone to degradation and losing mechanical strength which compromised its function as a
barrier. Silver sulfadiazine was successfully integrated into GEL-AXF fibers with its release
exhibiting near zero-order kinetics and anti-microbial properties against common bacterial
species encountered during wound healing. GEL-AXF fibers were biocompatible and did not
hinder fibroblast proliferation in vitro.
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Overall, these scaffolds show potential as a wound dressing material because of their
conformability, high surface to volume ratio and biocompatibility. However, its stability will
need to be improved to progress beyond the pre-clinical stage. This would be rectified by
blending in more stable polymers such as PCL, PLGA or PLA as additives that can be coelectrospun with arabinoxylan. This would reduce the degradability of the scaffold in aqueous
solution while maintaining biocompatibility. In turn, it is important that the amount of these
polymers are minimized so the natural component of arabinoxylan can illicit its natural, bioderived properties within the wound environment.

5.1.2. AXF foams
Arabinoxylan foams were fabricated and tested as a wound dressing material with 3M
Tegaderm Alginate foam as a commercial peer to compare against. A detailed summary of
properties of AXF foams are shown in Table 5.1. AXF foams exhibited a honeycomb
morphology with a highly porous structure that enable moisture and fluid exchange at the injurydressing interface. AXF foams in dry states were much stiffer than 3M Tegaderm Alginate
counterparts, illustrating its ability to be a barrier from the external environment. AXF foams can
be introduced with silver sulfadiazine to serve as a drug carrier to deliver a sustained dose of
anti-microbials to the wound site during a two day period. This delivery was validated by linear
release kinetics data and growth inhibition using the disk diffusion method. The in vitro
biocompatibility of the foams was also validated with cell viability and proliferation on par with
3M Alginate and non-treated groups. Sterilization of these scaffolds reduced bacterial endotoxin
content and ensured contamination was minimized.
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In summary, AXF foams possessed many material properties necessary to function as a
wound dressing material. Its mechanical stability in highly aqueous media will need to be
improved to fully achieve its potential. However, the ultimate application of AXF foams will be
to serve as an absorbent layer sandwiched between two polyurethane film layers micro-printed
with pores on its surface for wound fluid absorption. (Figure 5.1) This design will best optimize
the swelling properties of AXF foams while minimizing its weaknesses by surrounding it with a
much more stable polymer such as polyurethane. Polyurethane film is non-degradable, a
substrate for adhesives and is bio-inert to function as part of the dressing that directly interfaces
with the skin.135, 136 Polyurethane and arabinoxylan would be an ideal combination of polymers
whose prototype design would help treat against acute, moderately exudating wounds.

Figure 5.1: Diagram of polyurethane-arabinoxylan wound dressing material prototype.
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Table 5.1: Summary of AXF foam material properties.
Properties

Experimental test

Expected Outcomes

Results

Morphology

Scanning Electron
Microscopy

Highly porous, smooth surface, close to or
better than commercialized control



Mechanical Properties:
Shear Modulus

Rheometry

Close to or better than commercialized control



Porosity

Apparent Volume Method

Achieve porosity values between 70-90%; close
to or better than commercialized control



Swelling

Swelling Ratio

Maximal swelling above 200%; close to or
better than commercialized control



Cumulative Drug
Release Kinetics

Inductively Plasma Optical
Emission Spectrometry

Burst release kinetics in first six hours before
more controlled release; close to or better than
commercialized control



Bio-inert

LAL Endotoxin Assay

Reduction of bacterial endotoxins after
sterilization



Biocompatibility

Cell Viability and
Proliferation Assays;

Above 80% Cell Viability and double cell
number after 3 days; close to or better than
commercialized control



Anti-microbial
properties

Kirby Bauer Growth
Inhibition Assay

No bacterial lawns on inoculated agar gel; close
to or better than commercialized control



**Results subjectively rated from 1-3 checks in comparison to 3M Alginate foam dressing**
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5.2 Future work
This project attempted to comprehensively evaluate material properties of arabinoxylan
as electrospun fiber and foam platforms and evaluate its potential as a wound dressing material.
Although many of the properties in vitro have been successfully characterized, more work needs
to be done before it can be evaluated in a clinical setting. The three dimensional porosity of
arabinoxylan fibers and foams needs to be accurately measured using mercury porosimetry
method. Processing conditions such as AXF gel freezing temperature and lyophilization pressure
will need to be explored to examine its effect on its material properties. In vitro, additional cell
studies such as looking at macrophage and keratinocyte viability and proliferation should be
considered. Extracellular matrix production should also be considered by analyzing fibronectin
protein assembly through fluorescent antibody staining.137 Additionally, a blood clotting test
developed by Shih et al. would appropriately assess the clotting properties of AXF scaffolds in a
physiologically inclined environment.138
Next, in vivo testing models need to be conducted in detail to look at important
characteristics such as wound closure rate, neutrophil count, wound histology, extracellular
matrix production and mortality rate. Shin-Yeu et al. designed silver loaded chitosan gel
dressings for wound healing. This group conducted a study by creating wound incisions on the
dorsal region that were infected with P. aeruginosa before implanting the dressing on mice for
up to 14 days.139 The wound areas were measured to analyze the degree of closure and its scabs
were extracted, homogenized and plated on agar for bacteria quantification at 1, 2, 7 and 14 days.
Neutrophils from the mice’s blood were counted using a hemostasis analyzer to determine the
degree of inflammation after implanting the chitosan scaffold. The wound histology after
chitosan implantation was examined using hematoxylin and eosin, Masson Trichrome and Gram-
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Twort staining (H&E) to qualitatively assess inflammatory cell infiltration, collagen production
and bacteria presence. 139 Histology work from Sun’s group also used histology to look at dermal
differentiation, epithelial maturation and skin growth after implanting dextran hydrogels on mice
burn wound models during a three and five week period.105 Mortality rate also needs to be
considered during these studies. Mouse subjects in Shin-Yeu’s work were euthanized when their
physical condition deteriorated. Mice that survived after day 7 of the 14 day study were
classified as long term survivors while mortality rate was determined by the number of mice that
survived after Day 14.139 Implementing these in vivo studies using arabinoxylan polymers will
give a much clearer picture of its clinical effectiveness as a wound dressing material.
In literature, arabinoxylan has been largely unnoticed as potential wound dressing
material. However, its material properties, naturally derived origin and abundance are desirable
characteristics that warrant further investigation in vivo before clinical trials. This project aimed
to highlight the unique properties of arabinoxyan, its fabrication in nanofiber and foam
formulations and its application for treatment of acute, moderately exudating wounds. The in
vitro data from this project suggests a promising future for these platforms in advancing wound
dressing development. So far, there have been no entries of “arabinoxylan” found in any medical
device database stored by the United States Food and Drug Administration (FDA), indicating a
niche that has yet to be established commercially.140 This dissertation aimed to contribute and
catalyze this area in wound development.
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Abstract:
Polyamidoamine (PAMAM) dendrimers have emerged as an important class of
nanostructured materials and have found a broad range of applications. There is also an ongoing
effort to synthesize higher-complexity structures using PAMAM dendrimers as enabling building
blocks. Herein, we report for the first time the fabrication of electrospun nanocomposite fibers
composed of dendrimer derivatives, namely PEGylated PAMAM dendrimers, blended with a
small amount of high-molecular-weight polyethylene oxide (PEO). Morphological features and
mechanical properties of the resulting dendrimer fiber mats were assessed.
Keywords: electrospinning, dendrimer, nanofiber, PEGylation, fast Fourier transform
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6.1. Introduction
Polyamidoamine (PAMAM) dendrimers have emerged as an important class of
nanostructured materials and have found a broad range of applications by virtue of their highly
branched, nearly perfect monodisperse structures of defined sizes. These distinct nanodomain
features include a hydrophobic interior and a relatively hydrophilic surface presenting numerous
functional groups 141, 142 The structural versatility of PAMAM dendrimers has led to a vast array
of intriguing dendritic architectures as nanocarriers for therapeutic and diagnostic applications.143,
144

There is also an ongoing effort to synthesize higher-complexity structures using PAMAM

dendrimers as enabling building blocks 145-147 Of particular interest is the utility of PAMAM
dendrimers in construction of high-dimensional structures for drug delivery and tissue
engineering applications.148 For instance, PAMAM dendrimers are used as a cross-linker or
building block to construct cross-linked networks.149, 150
Electrospinning has been widely adopted to make fibers with desirable structural features
for drug delivery and tissue engineering application.151-157 A wide range of synthetic and natural
linear polymers have been electrospun into fibers with success.158 Although polymer molecular
weight and solution concentration are critical in successful electrospinning, intermolecular chain
entanglements within the polymer are very important to stable fiber formation as well. 158
Probably because of the widely recognized steric crowding on the dendrimer periphery
precluding chain entanglements, there is scarcity in the literature on the fabrication of dendrimer
fibers via electrospinning. Madani et al. reported electrospinning of blends of non-functionalized
PAMAM dendrimers and high-molecular-weight polyethylene oxide (PEO), in which PEO,
however, accounts for a large proportion (at least 30% by weight) of fiber mass.159 Our recent
work shows that PAMAM dendrimer can be hybridized with linear polymers, e.g., gelatin, and
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electrospun into fibers as a secondary component.60 Alternatively, PAMAM dendrimers can be
covalently coupled to fibers in a post-electrospinning step.160
In this paper, we report for the first time electrospun nanocomposite fibers composed of
dendrimer derivatives, namely PEGylated PAMAM dendrimers, blended with a small amount of
high-molecular-weight polyethylene oxide (PEO) (6.25% by weight). The new dendrimercontaining nanocomposite fibers represent a new structure with added complexity of dendrimer
and fibrous mat. PEGylation reduces the cytotoxicity of the resulting conjugate of the
nanomaterial due to the superb biocompatibility of PEG.161-163 PEGylated dendrimers may
encourage greater retention time in the circulatory system due to the stealth properties of PEG.164
We envision that new dendrimer-containing fibers will broaden the use of dendrimers in
biomedical applications such as drug delivery, and the ease of fabrication via electrospinning
will allow this new platform to be readily translatable.

6.2. Experimental section
6.2.1. Synthesis of PEGylated PAMAM dendrimer conjugates

PAMAM dendrimer G3.0 was used as the underlying core for the synthesis because of its
combination of possessing low cytotoxicity at high molar concentrations and a relatively large
number of surface groups for functionalization. 161-163 Methoxypolyethylene glycol (mPEG, 2000
g/mol) was coupled to PAMAM dendrimer G3.0 at feed molar ratios of 32:1 and 16:1,
respectively following the method published by us.165 These two molar ratios were chosen to
ensure the resulting PEGylated dendrimer conjugates with discrete degrees of PEGylation could
be achieved. 165 PEGylated G3.0 conjugates were purified using SnakeSkin tubing with 7000
MWCO and freeze dried.
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6.2.2. Electrospinning
Electrospinning solutions of mPEG or mPEG-G3.0 with or without high-molecularweight PEO (Mv = 900,000 g/mol) additive were prepared in 1,1,1,3,3,3-hexafluoro-2-propanol
(HFP) and tested for fiber formation (Table 6.1). The electrospinning solution was then drawn
up through a blunt-end needle (18G×1½ in) on a 5 ml syringe. The syringe was loaded into a
syringe pump, delivering the solution to the needle orifice 30 cm away from the collecting
mandrel at a rate of 2 ml/h. The needle and the collection target were connected to a positive
electrode (+ 20 kV) and the earth ground of a high voltage power supply (Spellman CZE100R,
Spellman High Voltage Electronics Corporation), respectively. Fibers were collected on a
rounded, stainless steel mandrel (120 mm length with 6 mm diameter) rotating at 500 rpm.
Table 6.1. Electrospinning conditions tested for fiber formation.
Polymer (A/B)

A

B

(% w/v)

(% w/v)

mPEG2000/PEO

20‐25

0

No

mPEG2000/PEO

20‐25

0.05‐0.1

Yes

mPEG‐G3.0 (32:1)/PEO

20‐40

0

No

mPEG‐G3.0 (32:1)/PEO

15

1

Yes

mPEG‐G3.0 (16:1)/PEO

15

1

Yes

100

Fiber formation

6.2.3. 1H NMR spectroscopy
1

H NMR spectra were recorded on a Varian Mercury 600 MHz spectrometer. Deuterium

oxide (D2O, 99.9%) was used as solvent in 1H NMR measurements. 1H NMR spectroscopy was
applied to characterize PEGylated G3.0 conjugates and determine actual degrees of PEGylation.
6.2.4. Scanning electron microscopy (SEM)
Prior to SEM imaging, scaffolds were placed on a 1 cm diameter stub. The stub was
placed on a specimen holder and gold sputter coated. SEM images were taken on a JEOL JSM5610LV scanning electron microscope. One hundred randomly chosen fibers in each SEM image
were analyzed with UTHSCSA ImageToolTM software for fiber diameter and pore size
measurements.
6.2.5. Tensile testing
“Dog-bone” shaped samples (n=8) were obtained using a punch die (ODC Testing &
Molds) of the dimensions 19.0, 3.2 and 6.1 mm at its length, narrowest point and widest point,
respectively. Mechanical properties of the samples, including peak load, peak stress, modulus,
strain at break and energy to break, were tested using the MTS Bionix 200 Mechanical Testing
System in conjunction with TestWorks 4.0 software.
6.2.6. Fast fourier transform (FFT)

FFT technique was conducted to analyze the degree of fiber alignment and anisotropy
based on the work reported by Ayers and coworkers.154, 166 This was completed by taking the
SEM image of the scaffolds and converting its image information from the time domain to a
discrete frequency domain.154 The output image after FFT is grayscale pixels within a circle that
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have varying intensities with respect to its angle about the circle’s central point. Image
conversion and analysis was done on Image J software.
6.2.7. Statistical analysis
Statistical analysis was completed using unpaired t-test and the Mann-Whitney method
for subgroup comparison. A p-value less than 0.05 was considered statistically significant.
6.3. Results and discussion
For the demonstration of proof-of-concept, we chose amine-terminated PAMAM
dendrimer G3.0 as the underlying core (Scheme 6.1). We coupled mPEG2000 to the dendrimer
surface at feed molar ratios of 16:1 and 32:1, respectively, following a procedure previously
described.165 According to 1H NMR spectroscopy characterization (Figure 6.2), the degrees of
PEGylation of mPEG-G3.0 (16:1) and mPEG-G3.0 (32:1), i.e., percentages of dendrimer PEG
surface amines coupled to PEG, were 44% and 92%, respectively. For electrospinning
fabrication, coupling mPEG to PAMAM dendrimer G3.0 at 32:1 (i.e. 100% PEGylation) would
be more favorable. However, for drug delivery applications, an increased density of mPEG
chains can reduce the ability to couple drugs and moieties of interest due to steric hindrance of
PEG and reduced surface groups.165
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Figure 6.1. Schematic illustration of synthesis and electrospinning of mPEG-G3.0 blended with
a small amount of high-molecular-weight PEO 900,000 Da.
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Figure 6.2. 1H NMR spectrum of PEGylated PAMAM dendrimers. (A) mPEG-G3.0 (32:1) and
(B) mPEG-G3.0 (16:1). (peak a, (CH2CH2O)n ; peak b, CH3 CH2 CH2 O ; multiple peaks
2.4-3.45 ppm, methylene protons of dendrimer)
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It is challenging to make fibers out of pure dendrimers or PEGylated dendrimers because
of their highly compact structures, low chain entanglements, and high viscosity. Although it
remains controversial as to whether the presence of chain entanglements is essential for fiber
formation, it has been shown that a small fraction of PEO in electrospinning solution promotes
PEG fiber formation, which was attributed to fluid elasticity increase by PEO other than chain
entanglements.167 Electrospinning solutions of mPEG or mPEG-G3.0 with or without highmolecular-weight PEO additive were tested for electrospinning. After mPEG-G3.0 (16:1 and
32:1) (15% w/v in HFP) was blended with PEO (Mv=900,000 Da) (1% w/v), mPEG-G3.0 was
successfully electrospun into fiber mats, presumably as a result of promotion of both chain
entanglements and fluid elasticity. Fluid elasticity of mPEG-G3.0 solution was attributed to its
ability to adjust to stresses during a longer period of relaxation time. 167 Quantitative analysis of
rheological properties of mPEG-G3.0 electrospinning solutions is warranted for electrospinning
optimization and will be investigated in future work.
SEM images were used to characterize the electrospun mat’s fiber morphology. As
shown in Figure 6.3, mPEG-G3.0 (32:1) fibers exhibited some beads. The beading formation
could be due to applied charges breaking the solution up into droplets, otherwise known as
Rayleigh instability. According to the histograms of fiber size and pore size distributions shown
in Figure 6.4, the average diameters of mPEG-G3.0 (32:1) and mPEG-G3.0 (16:1) fibers were
3.8±2.3 µm and 4.2±2.8 µm, respectively. These relatively large variations in fiber diameter are
presumably attributed to high polymer concentrations (10% or higher), which have a tendency to
produce a non-normally distributed population of fibers.168 Average pore sizes of mPEG-G3.0
(32:1) and mPEG-G3.0 (16:1) fiber mats were 209 µm2 and 135 µm2, respectively. Typically,
electrospun scaffolds exhibit fiber diameters in the micrometer diameter range, but they can
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achieve nanometer fiber diameters under proper processing conditions. For this study, these
scaffolds were in the micron size range. This is likely due to the high concentration of mPEGG3.0 (Table 6.1) in electrospinning solution. One potential method to create fibers in the
nanoscale would be to 1) reduce the mPEG-G3.0 concentration below 10% to create nanofibers
as illustrated for PEO in literature and 2) increase the PEO additive concentration from 1%
(Table 6.1) up to 7% to improve spinnability. 168 The balance of those two parameters could help
achieve stable, nano-scaled fibers that can closely mimic the extracellular matrix, encouraging
cellular activity for tissue engineering applications. Having a nano-fiber topography can also
inspire a well-controlled drug release system for drug delivery applications because of the
scaffold’s high surface area to volume ratio.130
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A

B

C
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Figure 6.3. SEM images of electrospun fibers on the basis of mPEG-G3.0(32:1)(A, B) and
mPEG-G3.0(16:1)(C, D) at different magnifications.
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Figure 6.4. Fiber diameter and pore size distributions of mPEG-G3.0 (32:1) and mPEG-G3.0
(16:1) fiber scaffolds. (n=100)
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Uniaxial material testing on dendrimer fiber mats was attempted with the MTS Bionix
200 Mechanical Testing System.60, 124 Stress-strain curves of mPEG-G3.0 (32:1) fiber scaffolds
are shown in Figure 6.5. Electrospun mPEG-G3.0 (32:1) fibers exhibited poor mechanical
properties in terms of peak load (0.19 ± 0.09 N), peak stress (0.11 ± 0.07 MPa), modulus (3.0 ±
1.7 MPa), and energy to break (0.05 ± 0.03 N×mm). However, insufficient data was acquired for
mPEG-G3.0 (16:1) fiber mat using the same method because the mat’s thickness (0.1 ± 0 mm)
was much less than mPEG-G3.0 (32:1) mat’s thickness (0.7 ± 0.2 mm). Therefore, it was
difficult to preserve mat structure during the sample preparation. As a result, mPEG-G3.0 (16:1)
fiber mats were neither thick enough nor reproducible for accurate tensile measurements.
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Figure 6.5. Stress-strain curves of mPEG-G3.0 (32:1) fiber scaffolds (n=8).
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0.14

The fast Fourier transform (FFT) technique was conducted to characterize the degree of
fiber alignment and anisotropy following the work by Ayers et al.166 In particular, this analysis
was completed by converting SEM image information from the time domain to a discrete
frequency domain. The output image after FFT is grayscale pixels within a circle that has
varying intensities with respect to its angle about the circle’s central point. 166 Image conversion
and analysis was done by using Image J. Distinct peaks in the FFT plots indicates fiber
alignment. According to the FFT analysis result (Figure 6.6), the peak normalized intensities of
mPEG-G3.0 (32:1) and mPEG-G3.0 (16:1) fibers are 0.14 and 0.08, respectively. This result
quantitatively confirms that mPEG-G3.0 (16:1) scaffold possesses a higher degree of fiber
alignment, which, in turn, leads to a less porous structure as evidenced by smaller pore size. A
higher degree of fiber alignment enables an anisotropic scaffold that can better withstand
uniform axial loads and provide signaling cues for changes in cell proliferation, migration and
phenotype.154, 169
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Figure 6.6. Pixel intensity plots with respect to the angle of acquisition for electrospun mPEGG3.0 fiber scaffold.
Overall, the mPEG-G3.0 fiber scaffolds exhibit poor mechanical properties, which may
limit the scaffold’s stability to promote cellular activity and controlled release in tissue
engineering and drug delivery applications, respectively. To improve the physical properties of
dendrimer fiber scaffolds, additional polymers such as poly(lactic-co-glycolic acid) (PLGA) can
be coupled to PEG to form PLGA-PEG copolymers on the dendrimer surface for drug delivery
applications.170 PLGA has high mechanical strength and elasticity in an early time course. 130 Its
material properties such as hydrophilicity and elasticity can be controlled by changing its
polymer concentration or ratio of lactic to glycolic acid. However, optimization of these
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electrospinning additives is necessary to improve the physical properties while maintaining the
original properties of the mPEG-G3.0 conjugates. In addition, dendrimer surface groups may be
chemically functionalized to form a cross-linked network following electrospinning to further
enhance structural stability and mechanical properties of dendrimer fibrous mats.
By theory, a critical concentration (c*) for chain entanglements in solution should be surpassed
for successful fiber formation during electrospinning.158 This parameter can be theoretically
estimated based on Equation 1:
∗

3 /4

(1) ref. [167]

where M is molecular weight, NA is the Avogadro number, and Rg is the radius of gyration of the
polymer and can be estimated using Equation 2.
0.215

.

Å

(2) ref. [171]

Although PEG chain interpenetration among PEGylated dendritic molecules may help
with chain entanglements, PEGylated dendrimers are highly compact. Rg of PAMAM G3.0 fully
conjugated with PEG of 5000 Da was reported to be 6.27 nm [172], which was only twice the
radius of gyration of linear PEG 5000 Da (3.08 nm according to Equation 2 [171]). The same is
true for PAMAM G3.0 coupled with mPEG2000 due to an even smaller Rg. Not surprisingly, the
highest concentration 40% w/v tested for mPEG-G3.0 (32:1) did not generate fibers. Only
droplets deposited on the mandrel were observed during the electrospinning process. Therefore,
this estimation suggested a slight chance of electrospinning PEGylated dendrimers alone into
fibers due to the difficulty of achieving a critical concentration and further substantiated the use
of long PEO as a fiber forming additive. Nonetheless, PEO additive contributed to only 6.25%
fiber mass, the structure and properties of the resulting fiber mats are predominately influenced
by PEGylated PAMAM dendrimers.
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In future work, the in vitro cytocompatibility of the scaffolds will be assessed. Antimicrobial tests such as the Kirby-Bauer assay or turbidity measurement will be utilized to
validate the sterility of the scaffold before application. The encapsulation and efficacy of relevant
drugs, growth factors and anti-microbial agents will be tested to confirm the functions of
bioactive molecules within our novel fiber system. Additional polymers such as PLGA may be
incorporated to enhance the scaffold’s mechanical stability. Lastly, in vivo studies will be
planned to examine its pre-clinical potential in physiological conditions.
6.4. Conclusions
In summary, we have successfully fabricated electrospun dendrimer-containing
nanocomposite fibers. Morphologically, the mats possessed a uni-modal, non-normal distribution
of fibers on the micrometer scale. Fiber alignment is influenced by the degree of PEGylation on
the dendrimer surface. The dendrimer fibrous mats show weak mechanical properties that can be
improved by adding more stable copolymers such as PLGA without compromising the
functionality of dendrimers. In addition, dendrimer surface groups may be chemically
functionalized to form a cross-linked network following electrospinning to further enhance
structural stability and mechanical properties of dendrimer fibrous mats. Further improvements
in the mat’s mechanical properties can make it a potential platform for drug delivery and tissue
engineering applications.
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Appendix A – Statistical analysis: Electrospinning of arabinoxylan as a novel
fiber scaffold:
Morphology: Fiber Diameter & Pore Size
Monday, October 14, 2013, 10:03:33 AM

One Way Analysis of Variance
Data source: Data 1 in Fiber diameter Gel_AXF
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Monday, October 14, 2013, 10:03:33 AM

Data source: Data 1 in Fiber diameter Gel_AXF
Group
N
Gel-AXF 1:1 100
Gel-AXF 2:1 100
Gel-AXF 4:1 100

Missing
0
0
0

Median
0.410
0.560
1.015

25%
0.350
0.430
0.610

75%
0.490
0.670
1.350

H = 103.971 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
Gel-AXF 4:1 vs Gel-AXF 1:1
Gel-AXF 4:1 vs Gel-AXF 2:1
Gel-AXF 2:1 vs Gel-AXF 1:1

Diff of Ranks
12488.000
6767.500
5720.500

q
14.396
7.801
6.594

P<0.05
Yes
Yes
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Monday, October 14, 2013, 10:15:48 AM

One Way Analysis of Variance
Data source: Data 1 in Pore Size Gel_AXF
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks
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Monday, October 14, 2013, 10:15:48 AM

Data source: Data 1 in Pore Size Gel_AXF
Group
N
Gel-AXF 1:1 100
Gel-AXF 2:1 100
Gel-AXF 4:1 100

Missing
0
0
0

Median
0.505
1.195
2.620

25%
0.333
0.725
1.215

75%
0.808
1.795
4.845

H = 117.749 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
Gel-AXF 4:1 vs Gel-AXF 1:1
Gel-AXF 4:1 vs Gel-AXF 2:1
Gel-AXF 2:1 vs Gel-AXF 1:1

Diff of Ranks
13280.000
5843.500
7436.500

q
15.309
6.736
8.573

P<0.05
Yes
Yes
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Tensile Properties
Monday, October 14, 2013, 10:45:06 AM

One Way Analysis of Variance
Data source: Thickness in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
1:1 Gel-AXF
2:1 Gel-AXF
4:1 Gel-AXF

N
12
12
12

Source of Variation
Between Groups
Residual
Total

Passed (P = 0.238)

Passed (P = 0.258)
Missing
0
0
0
DF
2
33
35

Mean
0.00842
0.0113
0.0169

Std Dev
0.00133
0.00152
0.000772

SS
0.000445
0.0000512
0.000496

SEM
0.000384
0.000437
0.000223

MS
0.000222
0.00000155

F
143.277

P
<0.001

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
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Comparisons for factor:
Comparison
4:1 Gel-AXF vs. 1:1 Gel-AXF
4:1 Gel-AXF vs. 2:1 Gel-AXF
2:1 Gel-AXF vs. 1:1 Gel-AXF

Diff of Means
0.00846
0.00562
0.00283

t
16.629
11.059
5.570

P
<0.001
<0.001
<0.001

P<0.050
Yes
Yes
Yes

Monday, October 14, 2013, 10:43:04 AM

One Way Analysis of Variance
Data source: Peak Load in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
1:1 Gel-AXF
2:1 Gel-AXF
4:1 Gel-AXF

N
12
12
12

Source of Variation
Between Groups
Residual
Total

Passed (P = 0.905)

Passed (P = 0.161)
Missing
0
0
0

Mean
0.288
0.588
1.380

Std Dev
0.0932
0.162
0.182

SEM
0.0269
0.0468
0.0524

DF
2
33
35

SS
7.643
0.748
8.391

MS
3.822
0.0227

F
168.687

P
<0.001

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
4:1 Gel-AXF vs. 1:1 Gel-AXF
4:1 Gel-AXF vs. 2:1 Gel-AXF
2:1 Gel-AXF vs. 1:1 Gel-AXF

Diff of Means
1.092
0.792
0.300

t
17.778
12.888
4.890

Data source: Peak Stress in Notebook1

Equal Variance Test:
Group Name
1:1 Gel-AXF
2:1 Gel-AXF

N
12
12

Passed (P = 0.848)

Passed (P = 0.813)
Missing
0
0

P<0.050
Yes
Yes
Yes

Monday, October 14, 2013, 10:44:07 AM

One Way Analysis of Variance

Normality Test (Shapiro-Wilk)

P
<0.001
<0.001
<0.001

Mean
0.503
0.774

Std Dev
0.156
0.186

SEM
0.0452
0.0536
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4:1 Gel-AXF

12

Source of Variation
Between Groups
Residual
Total

0

1.207

0.149

DF
2
33
35

SS
3.027
0.892
3.918

MS
1.513
0.0270

0.0429
F
56.009

P
<0.001

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = <0.001).
Power of performed test with alpha = 0.050: 1.000

Monday, October 14, 2013, 10:46:54 AM

One Way Analysis of Variance
Data source: Modulus in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.987)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Monday, October 14, 2013, 10:46:54 AM

Data source: Modulus in Notebook1
Group
1:1 Gel-AXF
2:1 Gel-AXF
4:1 Gel-AXF

N
12
12
12

Missing
0
0
0

Median
5.731
22.148
46.463

25%
4.395
16.307
40.584

75%
7.851
32.483
51.656

H = 30.709 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
4:1 Gel-AXF vs 1:1 Gel-AXF
4:1 Gel-AXF vs 2:1 Gel-AXF
2:1 Gel-AXF vs 1:1 Gel-AXF

Diff of Ranks
286.000
146.000
140.000

q
7.836
4.000
3.836

P<0.05
Yes
Yes
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.
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Monday, October 14, 2013, 10:47:22 AM

One Way Analysis of Variance
Data source: Strain at Break in Notebook1
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Monday, October 14, 2013, 10:47:22 AM

Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Strain at Break in Notebook1
Group
1:1 Gel-AXF
2:1 Gel-AXF
4:1 Gel-AXF

N
12
12
12

Missing
0
0
0

Median
0.124
0.0645
0.0330

25%
0.107
0.0432
0.0273

75%
0.154
0.0952
0.0365

H = 25.607 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
1:1 Gel-AXF vs 4:1 Gel-AXF
1:1 Gel-AXF vs 2:1 Gel-AXF
2:1 Gel-AXF vs 4:1 Gel-AXF

Diff of Ranks
260.500
114.500
146.000

q
7.138
3.137
4.000

P<0.05
Yes
No
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Monday, October 14, 2013, 10:41:57 AM

One Way Analysis of Variance
Data source: Energy to Break in Notebook1
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Monday, October 14, 2013, 10:41:57 AM

Data source: Energy to Break in Notebook1
Group
1:1 Gel-AXF
2:1 Gel-AXF
4:1 Gel-AXF

N
12
12
12

Missing
0
0
0

Median
0.145
0.128
0.183

25%
0.0895
0.0847
0.134
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75%
0.186
0.136
0.191

H = 7.576 with 2 degrees of freedom. (P = 0.023)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = 0.023)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
4:1 Gel-AXF vs 2:1 Gel-AXF
4:1 Gel-AXF vs 1:1 Gel-AXF
1:1 Gel-AXF vs 2:1 Gel-AXF

Diff of Ranks
142.000
74.000
68.000

q
3.891
2.028
1.863

P<0.05
Yes
No
No

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Carbohydrate Assay

Saturday, March 28, 2015, 9:43:12 PM

One Way Analysis of Variance
Data source: Data 1 in Carbohydrate Assay compiled
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.457)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Saturday, March 28, 2015, 9:43:12 PM

Data source: Data 1 in Carbohydrate Assay compiled
Group
Gel-AXF 1:1
Gel-AXF 2:1
Gel-AXF 4:1

N
10
10
10

Missing
0
0
0

Median
9.695
3.895
1.615

25%
7.833
2.163
0.578

75%
15.637
5.235
2.740

H = 21.399 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
Gel-AXF 1:1 vs Gel-AXF 4:1
Gel-AXF 1:1 vs Gel-AXF 2:1

Diff of Ranks
180.000
114.000

q
6.466
4.095
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P<0.05
Yes
Yes

Gel-AXF 2:1 vs Gel-AXF 4:1

66.000

2.371

No

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Saturday, March 28, 2015, 9:44:04 PM

One Way Analysis of Variance
Data source: Data 1 in Carbohydrate Assay compiled
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.458)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Saturday, March 28, 2015, 9:44:04 PM

Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 1 in Carbohydrate Assay compiled
Group
AXF Pct Loss Gel-AXF 1:1
AXF Pct Loss Gel-AXF 2:1
AXF Pct Loss Gel-AXF 4:1

N
10
10
10

Missing
0
0
0

Median
40.305
29.405
18.385

25%
34.363
28.065
17.260

75%
42.167
31.137
19.422

H = 25.806 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
GEL-AXF 1:1 Pct Loss vs GEL-AXF 4:1 Pct Loss
GEL-AXF 1:1 Pct Loss vs GEL-AXF 2:1 Pct Loss
GEL-AXF 2:1 Pct Loss vs GEL-AXF 4:1 Pct Loss

Diff of Ranks
200.000
100.000
100.000

q
7.184
3.592
3.592

P<0.05
Yes
Yes
Yes

Drug Release Kinetics
Wednesday, March 25, 2015, 3:24:16 PM

One Way Analysis of Variance
Data source: Data 1 in Drug Release Study March
Normality Test (Shapiro-Wilk)

Passed (P = 0.475)

Equal Variance Test:

Passed (P = 0.159)

Group Name
1:1 Gel-AXF 1 h

Missing
0

N
6

Mean
5.045

Std Dev
1.727
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SEM
0.705

2:1 Gel-AXF 1 h
4:1 Gel-AXF 1 h

6
6

Source of Variation
Between Groups
Residual
Total

0
0
DF
2
15
17

4.103
2.193
SS
25.340
19.170
44.510

0.807
0.450
MS
12.670
1.278

0.329
0.184
F
9.914

P
0.002

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = 0.002).
Power of performed test with alpha = 0.050: 0.944
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
1:1 Gel-AXF vs. 4:1 Gel-AXF
2:1 Gel-AXF vs. 4:1 Gel-AXF
1:1 Gel-AXF vs. 2:1 Gel-AXF

Diff of Means
2.852
1.910
0.942

t
4.370
2.926
1.443

P
0.002
0.021
0.170

P<0.050
Yes
Yes
No

Wednesday, March 25, 2015, 3:34:35 PM

One Way Analysis of Variance
Data source: Data 1 in Drug Release Study March
Normality Test (Shapiro-Wilk)

Passed (P = 0.889)

Equal Variance Test:

Passed (P = 0.126)

Group Name
1:1 Gel-AXF 2 h
2:1 Gel-AXF 2 h
4:1 Gel-AXF 2 h

Missing
0
0
0

N
6
6
6

Source of Variation
Between Groups
Residual
Total

DF
2
15
17

Mean
8.495
7.291
4.186
SS
59.316
34.778
94.094

Std Dev
2.259
1.120
0.773
MS
29.658
2.319

SEM
0.922
0.457
0.316
F
12.792

P
<0.001

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = <0.001).
Power of performed test with alpha = 0.050: 0.986
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
1:1 Gel-AXF vs. 4:1 Gel-AXF
2:1 Gel-AXF vs. 4:1 Gel-AXF
1:1 Gel-AXF vs. 2:1 Gel-AXF

Diff of Means
4.309
3.105
1.204

t
4.901
3.532
1.369
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P
<0.001
0.006
0.191

P<0.050
Yes
Yes
No

Wednesday, March 25, 2015, 3:35:09 PM

One Way Analysis of Variance
Data source: Data 1 in Drug Release Study March
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.889)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Wednesday, March 25, 2015, 3:35:09 PM

Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 1 in Drug Release Study March
Group
1:1 Gel-AXF 6 h
2:1 Gel-AXF 6 h
4:1 Gel-AXF 6 h

N
6
6
6

Missing
0
0
0

Median
12.564
8.837
6.338

25%
8.273
8.045
4.648

75%
15.215
10.733
7.351

H = 10.889 with 2 degrees of freedom. (P = 0.004)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = 0.004)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
1:1 Gel-AXF 6 vs 4:1 Gel-AXF 6
1:1 Gel-AXF 6 vs 2:1 Gel-AXF 6
2:1 Gel-AXF 6 vs 4:1 Gel-AXF 6

Diff of Ranks
59.000
16.000
43.000

q
4.512
1.224
3.288

P<0.05
Yes
No
No

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Wednesday, March 25, 2015, 3:35:41 PM

One Way Analysis of Variance
Data source: Data 1 in Drug Release Study March
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
1:1 Gel-AXF 12 h
2:1 Gel-AXF 12 h

N
6
6

Passed (P = 0.671)

Passed (P = 0.332)
Missing
0
0

Mean
14.541
10.978

Std Dev
4.084
2.320
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SEM
1.667
0.947

4:1 Gel-AXF 12 h

6

Source of Variation
Between Groups
Residual
Total

0
DF
2
15
17

7.832
SS
135.204
123.123
258.326

1.600
MS
67.602
8.208

0.653
F
8.236

P
0.004

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = 0.004).
Power of performed test with alpha = 0.050: 0.885
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
1:1 Gel-AXF vs. 4:1 Gel-AXF
1:1 Gel-AXF vs. 2:1 Gel-AXF
2:1 Gel-AXF vs. 4:1 Gel-AXF

Diff of Means
6.709
3.563
3.146

t
4.056
2.154
1.902

P
0.003
0.093
0.077

P<0.050
Yes
No
No

Wednesday, March 25, 2015, 3:36:14 PM

One Way Analysis of Variance
Data source: Data 1 in Drug Release Study March
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
1:1 Gel-AXF 24 h
2:1 Gel-AXF 24 h
4:1 Gel-AXF 24 h
Source of Variation
Between Groups
Residual
Total

N
6
6
6

Passed (P = 0.935)

Passed (P = 0.338)
Missing
0
0
0
DF
2
15
17

Mean
17.283
13.488
9.487

SS
182.413
247.849
430.262

Std Dev
5.332
4.211
1.847
MS
91.207
16.523

SEM
2.177
1.719
0.754

F
5.520

P
0.016

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = 0.016).
Power of performed test with alpha = 0.050: 0.680
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
1:1 Gel-AXF vs. 4:1 Gel-AXF
2:1 Gel-AXF vs. 4:1 Gel-AXF
1:1 Gel-AXF vs. 2:1 Gel-AXF

Diff of Means
7.797
4.001
3.796

t
3.322
1.705
1.617
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P
0.014
0.206
0.127

P<0.050
Yes
No
No

Wednesday, March 25, 2015, 3:37:00 PM

One Way Analysis of Variance
Data source: Data 1 in Drug Release Study March
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
1:1 Gel-AXF 48 h
2:1 Gel-AXF 48 h
4:1 Gel-AXF 48 h

N
6
6
6

Source of Variation
Between Groups
Residual
Total

Passed (P = 0.912)

Passed (P = 0.057)
Missing
0
0
0
DF
2
15
17

Mean
20.894
16.965
10.596

SS
324.125
573.210
897.335

Std Dev
7.882
6.977
1.957
MS
162.062
38.214

SEM
3.218
2.848
0.799
F
4.241

P
0.035

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = 0.035).
Power of performed test with alpha = 0.050: 0.523
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
1:1 Gel-AXF vs. 4:1 Gel-AXF
2:1 Gel-AXF vs. 4:1 Gel-AXF
1:1 Gel-AXF vs. 2:1 Gel-AXF

Diff of Means
10.298
6.370
3.929

t
2.885
1.785
1.101

P
0.034
0.180
0.288

P<0.050
Yes
No
No

WST-1 Assay
Note: The multiple comparisons on ranks do not include an adjustment for ties.
Thursday, June 18, 2015, 10:02:55 AM

One Way Analysis of Variance
Data source: Data 1 in wst compiled run
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.121)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Thursday, June 18, 2015, 10:02:55 AM

Data source: Data 1 in wst compiled run
Group
1-1 0.05 mg/ml

N
8

Missing
0

Median
1.035

25%
1.023
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75%
1.142

1-1 0.5 mg/ml
1-1 5 mg/ml
1-1 25 mg/ml

8
8
8

0
0
0

1.430
1.615
2.325

1.188
1.363
1.635

1.533
1.730
2.598

H = 20.590 with 3 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
1-1 25 mg/ml vs 1-1 0.05 mg/ml
1-1 25 mg/ml vs 1-1 0.5 mg/ml
1-1 25 mg/ml vs 1-1 5 mg/ml
1-1 5 mg/ml vs 1-1 0.05 mg/ml
1-1 5 mg/ml vs 1-1 0.5 mg/ml
1-1 0.5 mg/ml vs 1-1 0.05 mg/m

Diff of Ranks
162.000
103.000
51.000
111.000
52.000
59.000

q
6.106
3.882
1.922
4.183
1.960
2.224

P<0.05
Yes
Yes
No
Yes
No
No

Note: The multiple comparisons on ranks do not include an adjustment for ties.
Thursday, June 18, 2015, 10:04:05 AM

One Way Analysis of Variance
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Thursday, June 18, 2015, 10:04:05 AM

Data source: Data 2 in wst compiled run
Group
2-1 0.05 mg/ml
2-1 0.5 mg/ml
2-1 5 mg/ml
2-1 25 mg/ml

N
8
8
8
8

Missing
0
0
0
0

Median
1.075
1.625
1.760
1.735

25%
0.972
1.355
1.672
1.445

75%
1.360
1.775
1.838
1.992

H = 13.778 with 3 degrees of freedom. (P = 0.003)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = 0.003)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
2-1 5 mg/ml vs 2-1 0.05 mg/ml

Diff of Ranks
129.500

q
4.881
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P<0.05
Yes

2-1 5 mg/ml vs 2-1 0.5 mg/ml
2-1 5 mg/ml vs 2-1 25 mg/ml
2-1 25 mg/ml vs 2-1 0.05 mg/ml
2-1 25 mg/ml vs 2-1 0.5 mg/ml
2-1 0.5 mg/ml vs 2-1 0.05 mg/m

43.500
21.000
108.500
22.500
86.000

1.639
0.791
4.089
0.848
3.241

No
Do Not Test
Yes
Do Not Test
No

Note: The multiple comparisons on ranks do not include an adjustment for ties.
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank
sums that enclose that comparison. For example, if you had four rank sums sorted in order, and found no significant
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1). Note that not testing the enclosed rank sums is a procedural rule,
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even
though one may appear to exist.

Thursday, June 18, 2015, 10:04:52 AM

One Way Analysis of Variance
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
4-1 0.05 mg/ml
4-1 0.5 mg/ml
4-1 5 mg/ml
4-1 25 mg/ml

N
8
8
8
8

Source of Variation
Between Groups
Residual
Total

Passed (P = 0.985)

Passed (P = 0.156)
Missing
0
0
0
0
DF
3
28
31

Mean
1.050
1.365
1.643
1.375
SS
1.409
3.834
5.243

Std Dev
0.246
0.270
0.473
0.437
MS
0.470
0.137

SEM
0.0869
0.0955
0.167
0.154

F
3.430

P
0.030

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = 0.030).
Power of performed test with alpha = 0.050: 0.538
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
4-1 5 mg/ml vs. 4-1 0.05 mg/ml
4-1 25 mg/ml vs. 4-1 0.05 mg/
4-1 0.5 mg/m vs. 4-1 0.05 mg/
4-1 5 mg/ml vs. 4-1 0.5 mg/ml
4-1 5 mg/ml vs. 4-1 25 mg/ml
4-1 25 mg/ml vs. 4-1 0.5 mg/ml

Diff of Means
0.593
0.325
0.315
0.278
0.268
0.01000

t
3.202
1.757
1.702
1.500
1.446
0.0540
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P
0.020
0.376
0.343
0.375
0.293
0.957

P<0.050
Yes
No
No
No
No
No

Thursday, June 18, 2015, 10:05:58 AM

One Way Analysis of Variance
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
1-1 0.05 mg/ml
2-1 0.05 mg/ml
4-1 0.05 mg/ml

N
8
8
8

Source of Variation
Between Groups
Residual
Total

Passed (P = 0.066)

Passed (P = 0.420)
Missing
0
0
0
DF
2
21
23

Mean
1.084
1.130
1.050

Std Dev
0.149
0.216
0.246

SS
0.0258
0.906
0.932

MS
0.0129
0.0431

SEM
0.0528
0.0763
0.0869
F
0.299

P
0.745

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.745).
Power of performed test with alpha = 0.050: 0.049
The power of the performed test (0.049) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Thursday, June 18, 2015, 10:06:40 AM

One Way Analysis of Variance
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
1-1 0.5 mg/ml
2-1 0.5 mg/ml
4-1 0.5 mg/ml

N
8
8
8

Source of Variation
Between Groups
Residual
Total

Passed (P = 0.588)

Passed (P = 0.850)
Missing
0
0
0
DF
2
21
23

Mean
1.371
1.603
1.365
SS
0.293
1.218
1.511

Std Dev
0.220
0.229
0.270
MS
0.147
0.0580

SEM
0.0779
0.0809
0.0955
F
2.527

P
0.104

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.104).
Power of performed test with alpha = 0.050: 0.278
The power of the performed test (0.278) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.
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Thursday, June 18, 2015, 10:07:12 AM

One Way Analysis of Variance
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.573)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Thursday, June 18, 2015, 10:07:12 AM

Data source: Data 2 in wst compiled run
Group
1-1 5 mg/ml
2-1 5 mg/ml
4-1 5 mg/ml

N
8
8
8

Missing
0
0
0

Median
1.615
1.760
1.695

25%
1.363
1.672
1.265

75%
1.730
1.838
2.070

H = 2.117 with 2 degrees of freedom. (P = 0.347)
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.347)

Thursday, June 18, 2015, 10:07:54 AM

One Way Analysis of Variance
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
1-1 25 mg/ml
2-1 25 mg/ml
4-1 25 mg/ml

N
8
8
8

Source of Variation
Between Groups
Residual
Total

Passed (P = 0.637)

Passed (P = 0.515)
Missing
0
0
0

Mean
2.250
1.668
1.375

Std Dev
0.613
0.427
0.437

DF
2
21
23

SS
3.175
5.246
8.420

MS
1.587
0.250

SEM
0.217
0.151
0.154
F
6.355

P
0.007

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = 0.007).
Power of performed test with alpha = 0.050: 0.789
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05

142

Comparisons for factor:
Comparison
1-1 25 mg/ml vs. 4-1 25 mg/ml
1-1 25 mg/ml vs. 2-1 25 mg/ml
2-1 25 mg/ml vs. 4-1 25 mg/ml

Diff of Means
0.875
0.583
0.292

t
3.501
2.331
1.170

P
0.006
0.059
0.255

P<0.050
Yes
No
No

Thursday, June 18, 2015, 10:11:12 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:11:12 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
1-1 0.05 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.035
1.000

25%
1.023
1.000

75%
1.142
1.000

Mann-Whitney U Statistic= 8.000
T = 92.000 n(small)= 8 n(big)= 8 P(est.)= 0.008 P(exact)= 0.010
The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = 0.010)

Thursday, June 18, 2015, 10:11:34 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:11:34 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
1-1 0.5 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.430
1.000

25%
1.188
1.000

Mann-Whitney U Statistic= 8.000
T = 92.000 n(small)= 8 n(big)= 8 P(est.)= 0.008 P(exact)= 0.010

143

75%
1.533
1.000

The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = 0.010)

Thursday, June 18, 2015, 10:12:00 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:12:00 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
1-1 5 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.615
1.000

25%
1.363
1.000

75%
1.730
1.000

Mann-Whitney U Statistic= 0.000
T = 100.000 n(small)= 8 n(big)= 8 P(est.)= <0.001 P(exact)= <0.001
The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = <0.001)

Thursday, June 18, 2015, 10:12:20 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:12:20 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
1-1 25 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
2.325
1.000

25%
1.635
1.000

75%
2.598
1.000

Mann-Whitney U Statistic= 0.000
T = 100.000 n(small)= 8 n(big)= 8 P(est.)= <0.001 P(exact)= <0.001
The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = <0.001)
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Thursday, June 18, 2015, 10:12:36 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:12:36 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
2-1 0.05 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.075
1.000

25%
0.972
1.000

75%
1.360
1.000

Mann-Whitney U Statistic= 16.000
T = 84.000 n(small)= 8 n(big)= 8 P(est.)= 0.082 P(exact)= 0.105
The difference in the median values between the two groups is not great enough to exclude the possibility that the
difference is due to random sampling variability; there is not a statistically significant difference (P = 0.105)

Thursday, June 18, 2015, 10:13:24 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:13:24 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
2-1 0.5 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.625
1.000

25%
1.355
1.000

75%
1.775
1.000

Mann-Whitney U Statistic= 0.000
T = 100.000 n(small)= 8 n(big)= 8 P(est.)= <0.001 P(exact)= <0.001
The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = <0.001)
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Thursday, June 18, 2015, 10:13:52 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:13:52 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
2-1 5 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.760
1.000

25%
1.672
1.000

75%
1.838
1.000

Mann-Whitney U Statistic= 0.000
T = 100.000 n(small)= 8 n(big)= 8 P(est.)= <0.001 P(exact)= <0.001
The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = <0.001)

Thursday, June 18, 2015, 10:14:41 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:14:41 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
2-1 25 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.735
1.000

25%
1.445
1.000

75%
1.992
1.000

Mann-Whitney U Statistic= 8.000
T = 92.000 n(small)= 8 n(big)= 8 P(est.)= 0.008 P(exact)= 0.010
The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = 0.010)

Thursday, June 18, 2015, 10:15:01 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)
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Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:15:01 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
4-1 0.05 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.035
1.000

25%
0.920
1.000

75%
1.252
1.000

Mann-Whitney U Statistic= 32.000
T = 68.000 n(small)= 8 n(big)= 8 P(est.)= 1.000 P(exact)= 1.000
The difference in the median values between the two groups is not great enough to exclude the possibility that the
difference is due to random sampling variability; there is not a statistically significant difference (P = 1.000)

Thursday, June 18, 2015, 10:15:20 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:15:20 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
4-1 0.5 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.355
1.000

25%
1.100
1.000

75%
1.580
1.000

Mann-Whitney U Statistic= 8.000
T = 92.000 n(small)= 8 n(big)= 8 P(est.)= 0.008 P(exact)= 0.010
The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = 0.010)
Thursday, June 18, 2015, 10:15:43 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.062)
(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
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Thursday, June 18, 2015, 10:15:43 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
4-1 5 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.695
1.000

25%
1.265
1.000

75%
2.070
1.000

Mann-Whitney U Statistic= 8.000
T = 92.000 n(small)= 8 n(big)= 8 P(est.)= 0.008 P(exact)= 0.010
The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = 0.010)

Thursday, June 18, 2015, 10:16:13 AM

t-test
Data source: Data 2 in wst compiled run
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Thursday, June 18, 2015, 10:16:13 AM

Mann-Whitney Rank Sum Test
Data source: Data 2 in wst compiled run
Group
4-1 25 mg/ml
Normalized Control

N
8
8

Missing
0
0

Median
1.250
1.000

25%
1.018
1.000

75%
1.667
1.000

Mann-Whitney U Statistic= 16.000
T = 84.000 n(small)= 8 n(big)= 8 P(est.)= 0.082 P(exact)= 0.105
The difference in the median values between the two groups is not great enough to exclude the possibility that the
difference is due to random sampling variability; there is not a statistically significant difference (P = 0.105)

Trypan Blue Assay: Cell Viability
Wednesday, June 10, 2015, 12:39:14 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.862)

Passed (P = 0.608)

Group Name
Gel-AXF 1:1 blend 0 mg/ml
Gel-AXF 1:1 blend 0.05 mg/ml

N
3
3

Missing
0
0

Mean
97.800
95.133
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Std Dev
0.557
2.937

SEM
0.321
1.695

Gel-AXF 1:1 blend 0.5 mg/ml
Gel-AXF 1:1 blend 5 mg/ml
Gel-AXF 1:1 blend 25 mg/ml
Source of Variation
Between Groups
Residual
Total

DF
4
10
14

3
3
3

0
0
0

SS
40.157
41.060
81.217

98.600
97.767
94.467

MS
10.039
4.106

F
2.445

1.389
2.223
2.173

0.802
1.284
1.255

P
0.115

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.115).
Power of performed test with alpha = 0.050: 0.296
The power of the performed test (0.296) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Wednesday, June 10, 2015, 12:39:50 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.396)

Group Name
Gel-AXF 2:1 blend 0 mg/ml
Gel-AXF 2:1 blend 0.05 mg/ml
Gel-AXF 2:1 blend 0.5 mg/ml
Gel-AXF 2:1 blend 5 mg/ml
Gel-AXF 2:1 blend 25 mg/ml
Source of Variation
Between Groups
Residual
Total

Passed (P = 0.742)

DF
4
10
14

N
3
3
3
3
3
SS
3.143
11.947
15.089

Missing
0
0
0
0
0

Mean
97.800
98.367
97.500
97.100
97.200

MS
0.786
1.195

F
0.658

Std Dev
0.557
0.950
0.721
1.873
0.854

SEM
0.321
0.549
0.416
1.082
0.493

P
0.635

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.635).
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Wednesday, June 10, 2015, 12:40:27 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)

Passed (P = 0.618)
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Equal Variance Test:

Passed (P = 0.312)

Group Name
Gel-AXF 4:1 blend 0 mg/ml
Gel-AXF 4:1 blend 0.05 mg/ml
Gel-AXF 4:1 blend 0.5 mg/ml
Gel-AXF 4:1 blend 5 mg/ml
Gel-AXF 4:1 blend 25 mg/ml
Source of Variation
Between Groups
Residual
Total

DF
4
10
14

N
3
3
3
3
3

Missing
0
0
0
0
0

SS
20.876
65.513
86.389

Mean
97.800
94.633
96.200
97.733
97.100

MS
5.219
6.551

F
0.797

Std Dev
0.557
3.800
2.553
1.266
3.143

SEM
0.321
2.194
1.474
0.731
1.815

P
0.554

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.554).
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Wednesday, June 10, 2015, 12:42:20 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.811)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Wednesday, June 10, 2015, 12:42:20 PM

Data source: Raw Data in 6_9_15 compiled data
Group
Gel-AXF 1:1 blend 0.05 mg/ml
Gel-AXF 2:1 blend 0.05 mg/ml
Gel-AXF 4:1 blend 0.05 mg/ml

N
3
3
3

Missing
0
0
0

Median
94.600
98.400
94.700

25%
92.500
97.400
90.800

75%
98.300
99.300
98.400

H = 2.891 with 2 degrees of freedom. P(est.)= 0.236 P(exact)= 0.254
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.254)

Wednesday, June 10, 2015, 12:43:12 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)

Passed (P = 0.502)
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Equal Variance Test:

Passed (P = 0.397)

Group Name
Gel-AXF 1:1 blend 0.5 mg/ml
Gel-AXF 2:1 blend 0.5 mg/ml
Gel-AXF 4:1 blend 0.5 mg/ml

N
3
3
3

Source of Variation
Between Groups
Residual
Total

SS
8.660
17.940
26.600

DF
2
6
8

Missing
0
0
0

Mean
98.600
97.500
96.200

MS
4.330
2.990

F
1.448

Std Dev
1.389
0.721
2.553

SEM
0.802
0.416
1.474

P
0.307

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.307).
Power of performed test with alpha = 0.050: 0.094
The power of the performed test (0.094) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.
Wednesday, June 10, 2015, 12:43:54 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Passed (P = 0.084)

Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.913)

Group Name
Gel-AXF 1:1 blend 5 mg/ml
Gel-AXF 2:1 blend 5 mg/ml
Gel-AXF 4:1 blend 5 mg/ml
Source of Variation
Between Groups
Residual
Total

DF
2
6
8

N
3
3
3

Missing
0
0
0
SS
0.847
20.113
20.960

Mean
97.767
97.100
97.733

MS
0.423
3.352

F
0.126

Std Dev
2.223
1.873
1.266

SEM
1.284
1.082
0.731

P
0.884

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.884).
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.
Wednesday, June 10, 2015, 12:44:41 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.701)

Passed (P = 0.570)
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Group Name
Gel-AXF 1:1 blend 25 mg/ml
Gel-AXF 2:1 blend 25 mg/ml
Gel-AXF 4:1 blend 25 mg/ml
Source of Variation
Between Groups
Residual
Total

DF
2
6
8

N
3
3
3

Missing
0
0
0

SS
14.416
30.667
45.082

Mean
94.467
97.200
97.100

MS
7.208
5.111

F
1.410

Std Dev
2.173
0.854
3.143

SEM
1.255
0.493
1.815

P
0.315

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.315).
Power of performed test with alpha = 0.050: 0.090
The power of the performed test (0.090) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Trypan Blue Assay: Cell Proliferation

Wednesday, June 10, 2015, 12:45:25 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.370)

Group Name
Gel-AXF 1:1 blend 0 mg/ml
Gel-AXF 1:1 blend 0.05 mg/ml
Gel-AXF 1:1 blend 0.5 mg/ml
Gel-AXF 1:1 blend 5 mg/ml
Gel-AXF 1:1 blend 25 mg/ml
Source of Variation
Between Groups
Residual
Total

Passed (P = 0.900)

DF
4
10
14

N
3
3
3
3
3

Missing
0
0
0
0
0

SS
2888906666.667
20503066666.667
23391973333.333

Mean
101266.667
116133.333
131933.333
141933.333
125400.000

Std Dev
25562.733
32751.997
21822.313
71978.423
53556.325

MS
722226666.667
2050306666.667

F
0.352

SEM
14758.651
18909.375
12599.118
41556.762
30920.759
P
0.837

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.837).
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.
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Wednesday, June 10, 2015, 12:46:07 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.487)

Group Name
Gel-AXF 2:1 blend 0 mg/ml
Gel-AXF 2:1 blend 0.05 mg/ml
Gel-AXF 2:1 blend 0.5 mg/ml
Gel-AXF 2:1 blend 5 mg/ml
Gel-AXF 2:1 blend 25 mg/ml
Source of Variation
Between Groups
Residual
Total

Passed (P = 0.631)

DF
4
10
14

N
3
3
3
3
3

Missing
0
0
0
0
0

Mean
101266.667
126133.333
134333.333
154933.333
73533.333

SS
11862842666.667
11734533333.333
23597376000.000

Std Dev
25562.733
53787.111
35947.369
15738.276
27943.753

MS
2965710666.667
1173453333.333

F
2.527

SEM
14758.651
31054.003
20754.223
9086.498
16133.333
P
0.107

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.107).
Power of performed test with alpha = 0.050: 0.312
The power of the performed test (0.312) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Wednesday, June 10, 2015, 12:46:52 PM

One Way Analysis of Variance
Data source: Raw Data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.986)

Group Name
Gel-AXF 4:1 blend 0 mg/ml
Gel-AXF 4:1 blend 0.05 mg/ml
Gel-AXF 4:1 blend 0.5 mg/ml
Gel-AXF 4:1 blend 5 mg/ml
Gel-AXF 4:1 blend 25 mg/ml
Source of Variation
Between Groups
Residual
Total

Passed (P = 0.062)

DF
4
10
14

N
3
3
3
3
3

Missing
0
0
0
0
0

SS
12486624000.000
8598133333.333
21084757333.333

Mean
101266.667
178066.667
116066.667
151266.667
110266.667

Std Dev
25562.733
34368.784
30675.289
25738.169
29342.347

MS
3121656000.000
859813333.333

F
3.631

SEM
14758.651
19842.827
17710.386
14859.939
16940.812
P
0.045

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = 0.045).
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Power of performed test with alpha = 0.050: 0.518
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1
Gel-AXF 4:1 vs. Gel-AXF 4:1

Diff of Means
76800.000
67800.000
62000.000
50000.000
41000.000
35200.000
26800.000
14800.000
9000.000
5800.000

t
3.208
2.832
2.590
2.088
1.712
1.470
1.119
0.618
0.376
0.242

P
0.090
0.149
0.196
0.367
0.528
0.611
0.745
0.909
0.919
0.813

P<0.050
No
No
No
No
No
No
No
No
No
No

Wednesday, June 10, 2015, 12:49:48 PM

One Way Analysis of Variance
Data source: raw data in 6_9_15 compiled data
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.804)

Group Name
Gel-AXF 1:1 blend 0.05 mg/ml
Gel-AXF 2:1 blend 0.05 mg/ml
Gel-AXF 4:1 blend 0.05 mg/ml
Source of Variation
Between Groups
Residual
Total

Passed (P = 0.506)

DF
2
6
8

N
3
3
3

Missing
0
0
0

SS
6632808888.889
10293920000.000
16926728888.889

Mean
116133.333
126133.333
178066.667

Std Dev
32751.997
53787.111
34368.784

MS
3316404444.444
1715653333.333

F
1.933

SEM
18909.375
31054.003
19842.827
P
0.225

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.225).
Power of performed test with alpha = 0.050: 0.144
The power of the performed test (0.144) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Wednesday, June 10, 2015, 12:50:29 PM

One Way Analysis of Variance
Data source: raw data in 6_9_15 compiled data
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Passed (P = 0.627)

Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.825)

Group Name
Gel-AXF 1:1 blend 0.5 mg/ml
Gel-AXF 2:1 blend 0.5 mg/ml
Gel-AXF 4:1 blend 0.5 mg/ml

N
3
3
3

Source of Variation
Between Groups
Residual
Total

SS
591182222.222
5418800000.000
6009982222.222

DF
2
6
8

Missing
0
0
0

Mean
131933.333
134333.333
116066.667

Std Dev
21822.313
35947.369
30675.289

MS
295591111.111
903133333.333

SEM
12599.118
20754.223
17710.386

F
0.327

P
0.733

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.733).
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.
Wednesday, June 10, 2015, 12:51:01 PM

One Way Analysis of Variance
Data source: raw data in 6_9_15 compiled data
Passed (P = 0.654)

Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.124)

Group Name
Gel-AXF 1:1 blend 5 mg/ml
Gel-AXF 2:1 blend 5 mg/ml
Gel-AXF 4:1 blend 5 mg/ml
Source of Variation
Between Groups
Residual
Total

DF
2
6
8

N
3
3
3

Missing
0
0
0

Mean
141933.333
154933.333
151266.667

SS
269555555.556
12182080000.000
12451635555.556

Std Dev
71978.423
15738.276
25738.169

MS
134777777.778
2030346666.667

SEM
41556.762
9086.498
14859.939
F
0.0664

P
0.936

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.936).
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Wednesday, June 10, 2015, 12:51:53 PM

One Way Analysis of Variance
Data source: raw data in 6_9_15 compiled data
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Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.405)

Group Name
Gel-AXF 1:1 blend 25 mg/ml
Gel-AXF 2:1 blend 25 mg/ml
Gel-AXF 4:1 blend 25 mg/ml
Source of Variation
Between Groups
Residual
Total

Passed (P = 0.607)

DF
2
6
8

N
3
3
3

Missing
0
0
0

Mean
125400.000
73533.333
110266.667

SS
4268506666.667
9020213333.333
13288720000.000

Std Dev
53556.325
27943.753
29342.347

MS
2134253333.333
1503368888.889

SEM
30920.759
16133.333
16940.812

F
1.420

P
0.313

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.313).
Power of performed test with alpha = 0.050: 0.091
The power of the performed test (0.091) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Kirby-Bauer Growth Inhibition Assay
Friday, July 17, 2015, 2:28:18 PM

One Way Analysis of Variance
Data source: P. aeruginosa in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.958)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, July 17, 2015, 2:28:18 PM

Data source: P. aeruginosa in Notebook1
Group
Positive Control
4:1 GEL-AXF
Negative Control

N
2
2
2

Missing
0
0
0

Median
15.375
16.240
0.000

25%
15.000
15.230
0.000

75%
15.750
17.250
0.000

H = 3.824 with 2 degrees of freedom. P(est.)= 0.148 P(exact)= 0.200
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.200)
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Friday, July 17, 2015, 2:29:03 PM

One Way Analysis of Variance
Data source: S. aureus in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.773)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, July 17, 2015, 2:29:03 PM

Data source: S. aureus in Notebook1
Group
Positive Control
4:1 GEL-AXF
Negative Control

N
2
2
2

Missing
0
0
0

Median
23.830
9.510
0.000

25%
23.440
9.250
0.000

75%
24.220
9.770
0.000

H = 4.706 with 2 degrees of freedom. P(est.)= 0.095 P(exact)= 0.067
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.067)

Friday, July 17, 2015, 2:29:38 PM

One Way Analysis of Variance
Data source: E. faecalis in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.954)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, July 17, 2015, 2:29:38 PM

Data source: E. faecalis in Notebook1
Group
Positive Control
4:1 GEL-AXF
Negative Control

N
2
2
2

Missing
0
0
0

Median
28.250
9.385
0.000

25%
27.500
9.000
0.000

75%
29.000
9.770
0.000

H = 4.706 with 2 degrees of freedom. P(est.)= 0.095 P(exact)= 0.067
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.067)
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Appendix B – Statistical analysis: Arabinoxylan foams for wound healing
applications
Rheometry
Friday, December 05, 2014, 12:40:39 PM

One Way Analysis of Variance
Data source: Data 1 in Rheometry
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, December 05, 2014, 12:40:39 PM

Data source: Data 1 in Rheometry
Group
3M Tegaderm Alginate at 25 deg
AXF foam at 25 degrees Cels

N
16
16

Missing
0
0

Median
3030305.500
41721206.500

25%
2809754.750
36002237.500

75%
3276940.250
47338803.500

H = 23.273 with 1 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
AXF foam vs 3M Tegaderm

Diff of Ranks
256.000

q
6.822

P<0.05
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Friday, December 05, 2014, 12:56:54 PM

One Way Analysis of Variance
Data source: Data 1 in Rheometry
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 1 in Rheometry

158

Friday, December 05, 2014, 12:56:54 PM

Group
3M Tegaderm Alginate at 37 deg
AXF foam at 37 degrees Cels

N
16
16

Missing
0
0

Median
2933280.500
36400194.000

25%
2704148.750
30817059.500

75%
3154513.000
41458269.250

H = 23.273 with 1 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
AXF foam vs 3M Tegaderm

Diff of Ranks
256.000

q
6.822

P<0.05
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Friday, December 05, 2014, 12:59:51 PM

One Way Analysis of Variance
Data source: Data 2 in Rheometry
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, December 05, 2014, 12:59:51 PM

Data source: Data 2 in Rheometry
Group
3M Tegaderm Alginate at 25 deg
AXF foam at 25 degrees Cels

N
16
16

Missing
0
0

Median
526542.000
7478.929

25%
368287.275
6015.412

75%
751232.925
48108.995

H = 18.138 with 1 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
3M Tegaderm vs AXF foam

Diff of Ranks
226.000

q
6.023

P<0.05
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.
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Friday, December 05, 2014, 1:00:24 PM

One Way Analysis of Variance
Data source: Data 2 in Rheometry
Failed

Normality Test (Shapiro-Wilk)

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Friday, December 05, 2014, 1:00:24 PM

Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 2 in Rheometry
Group
3M Tegaderm Alginate at 37 deg
AXF foam at 37 degrees Cels

N
16
16

Missing
0
0

Median
486225.800
7075.829

25%
341389.825
5940.793

75%
691757.200
48064.872

H = 17.501 with 1 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
3M Tegaderm A vs AXF foam

Diff of Ranks
222.000

q
5.916

P<0.05
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Porosity
Friday, December 05, 2014, 1:25:17 PM

One Way Analysis of Variance
Data source: Data 1 in Porosity
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.195)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, December 05, 2014, 1:25:17 PM

Data source: Data 1 in Porosity
Group
Tegaderm 3M Alginate
AXF foam

N
8
8

Missing
0
0

Median
1.000
1.000

25%
1.000
1.000
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75%
1.000
1.000

H = 3.579 with 1 degrees of freedom. P(est.)= 0.059 P(exact)= 0.065
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.065)

Swelling
Friday, December 05, 2014, 1:04:39 PM

One Way Analysis of Variance
Data source: Copy of Data 1 in Swelling_revised
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Passed (P = 0.877)

Group Name
3M Tegaderm at 25 degrees Cels
AXF foam at 25 degrees Cels
Source of Variation
Between Groups
Residual
Total

Passed (P = 0.407)

DF
1
14
15

N
8
8

Missing
0
0

SS
1132300.537
1110306.534
2242607.070

Mean
1316.851
1848.899

Std Dev
303.442
257.950

MS
1132300.537
79307.610

F
14.277

SEM
107.283
91.199
P
0.002

The differences in the mean values among the treatment groups are greater than would be expected by chance; there
is a statistically significant difference (P = 0.002).
Power of performed test with alpha = 0.050: 0.936
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor:
Comparison
AXF foam vs. 3M Tegaderm

Diff of Means
532.048

t
3.779

P
0.002

P<0.050
Yes

Friday, December 05, 2014, 1:06:02 PM

One Way Analysis of Variance
Data source: Data 1 in Swelling_revised
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.440)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks
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Friday, December 05, 2014, 1:06:02 PM

Data source: Data 1 in Swelling_revised
Group
3M Tegaderm at 37 degrees Cels
AXF foam at 37 degrees Cels

N
8
8

Missing
0
0

Median
1017.442
1672.819

25%
960.002
1533.197

75%
1036.382
1879.197

H = 11.294 with 1 degrees of freedom. P(est.)= <0.001 P(exact)= <0.001
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
AXF foam vs 3M Tegaderm

Diff of Ranks
64.000

q
4.753

P<0.05
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

LAL Endotoxin Assay
Wednesday, July 01, 2015, 1:37:57 PM

t-test
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk)

Passed (P = 0.573)

Equal Variance Test:
Group Name
Unsterilized AXF
Sterilized AXF
Difference

Passed (P = 0.655)

N
8
8

Missing
0
0

Mean
5.301
3.416

Std Dev
1.099
0.871

SEM
0.388
0.308

1.885

t = 3.803 with 14 degrees of freedom. (P = 0.002)
95 percent confidence interval for difference of means: 0.822 to 2.948
The difference in the mean values of the two groups is greater than would be expected by chance; there is a
statistically significant difference between the input groups (P = 0.002).
Power of performed test with alpha = 0.050: 0.940
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Trypan Blue: Fibroblast Cell Viability
Wednesday, June 10, 2015, 1:06:55 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Wednesday, June 10, 2015, 1:06:55 PM

Data source: Data 2 in Compiled Data 6_8
Group
24 hr AXF
24 hr 3M Teg
24 hr None

N
8
8
8

Missing
0
0
0

Median
97.750
97.350
96.300

25%
94.950
94.650
94.450

75%
98.850
98.175
97.550

H = 2.008 with 2 degrees of freedom. (P = 0.366)
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.366)

Wednesday, June 10, 2015, 1:07:17 PM

One Way Analysis of Variance
Data source: Data 1 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Wednesday, June 10, 2015, 1:07:17 PM

Data source: Data 1 in Compiled Data 6_8
Group
72 hr AXF
72 hr 3M Teg
72 hr None

N
8
8
8

Missing
0
0
0

Median
97.100
97.500
97.300

25%
96.025
97.050
96.550

75%
97.575
97.750
97.675

H = 0.925 with 2 degrees of freedom. (P = 0.630)
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.630)
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Wednesday, June 10, 2015, 1:07:51 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Wednesday, June 10, 2015, 1:07:51 PM

Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 2 in Compiled Data 6_8
Group
24 hr AXF
72 hr AXF

N
8
8

Missing
0
0

Median
97.750
97.100

25%
94.950
96.025

75%
98.850
97.575

H = 0.799 with 1 degrees of freedom. P(est.)= 0.371 P(exact)= 0.382
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.382)

Wednesday, June 10, 2015, 1:08:17 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Wednesday, June 10, 2015, 1:08:17 PM

Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 2 in Compiled Data 6_8
Group
24 hr 3M Teg
72 hr 3M Teg

N
8
8

Missing
0
0

Median
97.350
97.500

25%
94.650
97.050

75%
98.175
97.750

H = 0.0249 with 1 degrees of freedom. P(est.)= 0.875 P(exact)= 0.878
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.878)

Wednesday, June 10, 2015, 1:08:49 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name

N

Passed (P = 0.057)

Passed (P = 0.343)
Missing

Mean

Std Dev

SEM
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24 hr None
72 hr None

8
8

Source of Variation
Between Groups
Residual
Total

0
0

95.787
96.925

DF
1
14
15

SS
5.176
38.244
43.419

1.919
1.335

0.678
0.472

MS
5.176
2.732

F
1.895

P
0.190

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.190).
Power of performed test with alpha = 0.050: 0.135
The power of the performed test (0.135) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Trypan Blue: Fibroblast Cell Proliferation
Wednesday, June 10, 2015, 1:11:41 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Wednesday, June 10, 2015, 1:11:41 PM

Data source: Data 2 in Compiled Data 6_8
Group
0 hr AXF
0 hr 3M Teg
0 hr None

N
8
8
8

Missing
0
0
0

Median
50000.000
50000.000
50000.000

25%
50000.000
50000.000
50000.000

75%
50000.000
50000.000
50000.000

H = 0.000 with 2 degrees of freedom. (P = 1.000)
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 1.000)

Wednesday, June 10, 2015, 1:12:08 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
24 hr AXF

N
8

Passed (P = 0.192)

Passed (P = 0.687)
Missing
0

Mean
166350.000

Std Dev
56132.369
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SEM
19845.789

24 hr 3M Teg
24 hr None

8
8

Source of Variation
Between Groups
Residual
Total

0
0

128825.000
205350.000

79448.056
75518.380

DF
2
21
23

SS
23427203333.333
106161035000.000
129588238333.333

28089.130
26699.779

MS
11713601666.667
5055287380.952

F
2.317

P
0.123

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.123).
Power of performed test with alpha = 0.050: 0.244
The power of the performed test (0.244) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Wednesday, June 10, 2015, 1:12:34 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Group Name
72 hr AXF
72 hr 3M Teg
72 hr None

N
8
8
8

Source of Variation
Between Groups
Residual
Total

Passed (P = 0.293)

Passed (P = 0.250)
Missing
0
0
0
DF
2
21
23

Mean
212025.000
302000.000
288718.750

Std Dev
47514.141
76911.823
108982.272

SS
37743529375.000
140351104687.500
178094634062.500

SEM
16798.786
27192.436
38531.052

MS
18871764687.500
6683385937.500

F
2.824

P
0.082

The differences in the mean values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.082).
Power of performed test with alpha = 0.050: 0.327
The power of the performed test (0.327) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. Negative results
should be interpreted cautiously.

Wednesday, June 10, 2015, 1:13:03 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.257)
(P < 0.050)
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Test execution ended by user request, ANOVA on Ranks begun
Wednesday, June 10, 2015, 1:13:03 PM

Kruskal-Wallis One Way Analysis of Variance on Ranks
Data source: Data 2 in Compiled Data 6_8
Group
0 hr AXF
24 hr AXF
72 hr AXF

N
8
8
8

Missing
0
0
0

Median
50000.000
161900.000
220000.000

25%
50000.000
111000.000
163700.000

75%
50000.000
205500.000
241000.000

H = 17.041 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
72 hr AXF vs 0 hr AXF
72 hr AXF vs 24 hr AXF
24 hr AXF vs 0 hr AXF

Diff of Ranks
110.500
29.000
81.500

q
5.525
1.450
4.075

P<0.05
Yes
No
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Wednesday, June 10, 2015, 1:14:25 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Wednesday, June 10, 2015, 1:14:25 PM

Data source: Data 2 in Compiled Data 6_8
Group
0 hr 3M Teg
24 hr 3M Teg
72 hr 3M Teg

N
8
8
8

Missing
0
0
0

Median
50000.000
94500.000
287000.000

25%
50000.000
65250.000
254000.000

75%
50000.000
193300.000
357000.000

H = 19.725 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
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All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
72 hr 3M Teg vs 0 hr 3M Teg
72 hr 3M Teg vs 24 hr 3M Teg
24 hr 3M Teg vs 0 hr 3M Teg

Diff of Ranks
123.000
54.000
69.000

q
6.150
2.700
3.450

P<0.05
Yes
No
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.

Wednesday, June 10, 2015, 1:15:27 PM

One Way Analysis of Variance
Data source: Data 2 in Compiled Data 6_8
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.110)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Wednesday, June 10, 2015, 1:15:27 PM

Data source: Data 2 in Compiled Data 6_8
Group
0 hr None
24 hr None
72 hr None

N
8
8
8

Missing
0
0
0

Median
50000.000
201700.000
279575.000

25%
50000.000
140150.000
186000.000

75%
50000.000
265500.000
394500.000

H = 17.197 with 2 degrees of freedom. (P = <0.001)
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = <0.001)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
72 hr None vs 0 hr None
72 hr None vs 24 hr None
24 hr None vs 0 hr None

Diff of Ranks
111.500
31.000
80.500

q
5.575
1.550
4.025

P<0.05
Yes
No
Yes

Note: The multiple comparisons on ranks do not include an adjustment for ties.
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Kirby-Bauer Growth Inhibition Assay
Friday, July 17, 2015, 2:39:33 PM

One Way Analysis of Variance
Data source: P. aeruginosa in Growth Inhibition data.JNB
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.897)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, July 17, 2015, 2:39:33 PM

Data source: P. aeruginosa in Growth Inhibition data.JNB
Group
Positive Control
AXF Foam
3M Alginate
Negative Control

N
2
2
2
2

Missing
0
0
0
0

Median
14.375
22.170
10.040
0.000

25%
10.500
21.090
8.750
0.000

75%
18.250
23.250
11.330
0.000

H = 6.241 with 3 degrees of freedom. P(est.)= 0.100 P(exact)= 0.038
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = 0.038)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
AXF Foam vs Negative Control
AXF Foam vs 3M Alginate
AXF Foam vs Positive Control
Positive Cont vs Negative Cont
Positive Cont vs 3M Alginate
3M Alginate vs Negative Cont

Diff of Ranks
12.000
7.000
5.000
7.000
2.000
5.000

q
3.464
2.021
1.443
2.021
0.577
1.443

P<0.05
No
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test

Note: The multiple comparisons on ranks do not include an adjustment for ties.
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank
sums that enclose that comparison. For example, if you had four rank sums sorted in order, and found no significant
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1). Note that not testing the enclosed rank sums is a procedural rule,
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even
though one may appear to exist.
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Friday, July 17, 2015, 2:40:49 PM

One Way Analysis of Variance
Data source: S. aureus in Growth Inhibition data.JNB
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.523)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, July 17, 2015, 2:40:49 PM

Data source: S. aureus in Growth Inhibition data.JNB
Group
Positive Control
AXF Foam
3M Alginate
Negative Control

N
2
2
2
2

Missing
0
0
0
0

Median
23.020
12.390
0.000
5.750

25%
22.600
11.500
0.000
5.750

75%
23.440
13.280
0.000
5.750

H = 6.829 with 3 degrees of freedom. P(est.)= 0.078 P(exact)= 0.010
The differences in the median values among the treatment groups are greater than would be expected by chance;
there is a statistically significant difference (P = 0.010)
To isolate the group or groups that differ from the others use a multiple comparison procedure.
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparison
Positive Cont vs 3M Alginate
Positive Cont vs Negative Cont
Positive Control vs AXF Foam
AXF Foam vs 3M Alginate
AXF Foam vs Negative Control
Negative Cont vs 3M Alginate

Diff of Ranks
12.000
8.000
4.000
8.000
4.000
4.000

q
3.464
2.309
1.155
2.309
1.155
1.155

P<0.05
No
Do Not Test
Do Not Test
Do Not Test
Do Not Test
Do Not Test

Note: The multiple comparisons on ranks do not include an adjustment for ties.
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank
sums that enclose that comparison. For example, if you had four rank sums sorted in order, and found no significant
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1). Note that not testing the enclosed rank sums is a procedural rule,
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even
though one may appear to exist.
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Friday, July 17, 2015, 2:41:10 PM

One Way Analysis of Variance
Data source: E. faecalis in Growth Inhibition data.JNB
Normality Test (Shapiro-Wilk)
Equal Variance Test:

Failed

Passed (P = 0.120)
(P < 0.050)

Test execution ended by user request, ANOVA on Ranks begun
Kruskal-Wallis One Way Analysis of Variance on Ranks

Friday, July 17, 2015, 2:41:10 PM

Data source: E. faecalis in Growth Inhibition data.JNB
Group
Positive Control
AXF Foam
3M Alginate
Negative Control

N
2
2
2
2

Missing
0
0
0
0

Median
27.615
12.320
0.000
0.000

25%
27.500
11.750
0.000
0.000

75%
27.730
12.890
0.000
0.000

H = 6.811 with 3 degrees of freedom. P(est.)= 0.078 P(exact)= 0.067
The differences in the median values among the treatment groups are not great enough to exclude the possibility that
the difference is due to random sampling variability; there is not a statistically significant difference (P = 0.067)
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Appendix C – Statistical analysis: Electrospinning of PEGylated
polyamidoamine dendrimer fibers
Morphology: Fiber Diameter
Friday, December 20, 2013, 10:05:56 AM

t-test
Data source: Data 1 in fiber diameter_mPEG_G3.0
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Friday, December 20, 2013, 10:05:56 AM

Mann-Whitney Rank Sum Test
Data source: Data 1 in fiber diameter_mPEG_G3.0
Group N
Col 1 101
Col 2 101

Missing
1
1

Median
3.210
3.235

25%
2.060
2.518

75%
4.803
4.500

Mann-Whitney U Statistic= 4552.500
T = 9602.500 n(small)= 100 n(big)= 100 (P = 0.275)
The difference in the median values between the two groups is not great enough to exclude the possibility that the
difference is due to random sampling variability; there is not a statistically significant difference (P = 0.275)

Morphology: Pore Size
Friday, December 20, 2013, 9:54:39 AM

t-test
Data source: Data 1 in Pore Size
Normality Test (Shapiro-Wilk)

Failed

(P < 0.050)

Test execution ended by user request, Rank Sum Test begun
Friday, December 20, 2013, 9:54:39 AM

Mann-Whitney Rank Sum Test
Data source: Data 1 in Pore Size
Group
32:1 PEGylation
16:1 PEGylation

N
100
100

Missing
0
0

Median
153.360
112.140

25%
87.120
49.560

Mann-Whitney U Statistic= 3582.000
T = 11468.000 n(small)= 100 n(big)= 100 (P = <0.001)
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75%
311.440
208.050

The difference in the median values between the two groups is greater than would be expected by chance; there is a
statistically significant difference (P = <0.001)
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